Document:

EX-10.1

 Exhibit 10.1 

[                
    , 2014] 
 NAME 
 ADDRESS 

CITY, STATE ZIP 
 Dear NAME, 

You currently participate in a special severance benefit program (the “Program”) which the Compensation Committee of the
Company’s Board of Directors approved for you and other senior executives. The terms and conditions governing your severance benefits were originally set forth in a letter agreement between you and the Company dated May 10, 2006 (the
“Original Letter Agreement”). The Original Letter Agreement was superseded by an amended letter agreement dated January 1, 2008 (the “2008 Letter Agreement”). This agreement (this “Agreement”) amends and restates
the 2008 Letter Agreement. Your Original Letter Agreement and 2008 Letter Agreement are no longer in effect, and your rights under the Program will be governed solely by the terms of this Agreement. 

PART ONE — DEFINITIONS 

For purposes of this letter agreement, the following definitions will be in effect: 

Average Bonus means the greater of (i) the average of the bonuses paid to you under the Company’s
cash incentive bonus program for the three (3) fiscal years of the Company (or such fewer number of fiscal years during which you were employed with the Company) ended immediately prior to the fiscal year in which the Change of Control is
effected, or (ii) the average of the bonuses paid to you under such program for the three (3) fiscal years of the Company (or such fewer number of fiscal years during which you were employed with the Company) ended immediately prior to the
fiscal year in which your Involuntary Termination occurs. Any bonus payment for a partial year of employment will be annualized before inclusion in your Average Compensation.  

Average Compensation means the average of your W-2 wages from the Company for the five (5) calendar years (or such fewer number of
calendar years of your employment with the Company) completed immediately prior to the calendar year in which the Change in Control is effected. Any W-2 wages for a partial year of employment will be annualized, in accordance with the frequency
which such wages are paid during such partial year, before inclusion in your Average Compensation.  

 Base Salary means the annual rate of base salary in effect for you immediately prior to
the Change in Control or (if greater) the annual rate of base salary in effect at the time of your Involuntary Termination. 

Board means the Company’s Board of Directors. 

Change in Control means: 

(i) the consummation of a merger or consolidation of the Company with or into another entity or any other corporate
reorganization, provided and only if more than fifty percent (50%) of the combined voting power of the continuing or surviving entity’s securities outstanding immediately after such merger, consolidation or other reorganization is owned by
persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization; 

(ii) the sale, transfer or other disposition of all or substantially all of the Company’s assets, or a liquidation or
dissolution of the Company; 
 (iii) any transaction as a result of which any person becomes the “beneficial owner”
(as defined in Rule 13d-3 of the Securities Exchange Act or 1934, as amended (the “Exchange Act”)), directly or indirectly, of securities of the Company representing at least fifty percent (50%) of the total voting power represented
by the Company’s then outstanding securities; or 
 (iv) a change in the composition of the Board over a period of
twelve (12) months or less such that a majority of the Board is no longer comprised of individuals who either (A) were members of the Board on the start date of that twelve (12)-month or shorter period (the “Original Directors”)
or (B) were elected or nominated for election to the Board with the affirmative vote of at least a majority of the aggregate number of Original Directors who were still in office at the time of the election or nomination plus any new Board
members whose election or nomination was previously so approved by such aggregate majority (other than an election or nomination of an individual whose initial assumption of office is in connection with an actual or threatened election contest
relating to the election of the directors of the Company). 
 For purposes of subparagraph (iii) above, the term “person”
shall have the same meaning as when used in Sections 13(d) and 14(d) of the Exchange Act, but shall exclude (i) a 

  
 Page 2 

 trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a parent or a
subsidiary and (ii) a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company. 

A transaction shall not constitute a Change of Control if its sole purpose is to change the state of the Company’s incorporation or to
create a holding company that will be owned in the same proportions by the persons who held the Company’s securities immediately before such transaction. 

Change in Control Severance Benefits means the various payments and benefits to which you may become entitled under Part Two of this
Agreement upon your Involuntary Termination in connection with a Change in Control or upon any earlier termination of your employment by the Company during the Pre-Closing Period other than a Termination for Cause. Such Change in Control Severance
Benefits may include one or more of the following: the accelerated vesting of your Equity Awards, a lump sum severance payment and continued health care coverage provided for you and your spouse and eligible dependents at the Company’s
expense. 
 Code means the Internal Revenue Code of 1986, as amended. 

Common Stock means the Company’s common stock. 

Company means Actuate Corporation, a Delaware corporation, and any successor corporation, whether or not resulting from a Change in
Control. 
 Equity Awards means all equity-based incentives, including without limitation Options, restricted stock,
restricted stock units, market stock units, stock appreciation rights, phantom stock rights and stock bonuses. 
 Fair Market Value
means, with respect to the shares of Common Stock subject to your Options, the closing selling price per share of Common Stock on the date in question, as such price is reported by the National Association of Securities Dealers on the Nasdaq
National Market and published in The Wall Street Journal. If there is no closing selling price reported for the Common Stock on the date in question, then the Fair Market Value will be the closing selling price on the last preceding date for
which such report exists. 
 Independent Auditors means the accounting firm serving as the Company’s independent certified
public accountants immediately prior to the Change in Control; provided, however, that in the event such accounting firm also serves as the independent certified public accountants for the corporation or other entity
effecting the Change in Control transaction with the Company or such accounting firm concludes that the services required of it hereunder would  

  
 Page 3 

 
adversely affect its independent status under applicable accounting standards or the performance of such services would otherwise be in contravention of applicable law, then the Independent
Auditors shall mean a nationally-recognized public accounting firm mutually acceptable to both you and the Company. 
 Involuntary
Termination means the termination of your Service which occurs by reason of: 
 (i) your involuntary and unilateral
dismissal or discharge by the Company other than a Termination For Cause, or 
 (ii) your voluntary resignation within one
hundred eighty (180) days following (A) a change in your position with the Company which materially reduces your duties and responsibilities, (B) a material change in your reporting responsibilities such that you are required to
report to a person whose duties, responsibilities and authority are materially less than those of the person to whom you report as of the date of this letter agreement (including any change which would no longer require you to report directly to the
Board, if your reporting responsibility is to the Board as the date of this letter agreement),(C) a 15% or greater reduction in either your annual base salary or your target bonus under any corporate-performance based bonus or incentive program or a
30% or greater reduction in the aggregate level of your annual base salary and your target bonus under any corporate-performance based bonus or incentive program, (D) a change in the geographic location of your place of employment of more than
fifty (50) miles, (E) any material breach of the terms of this Agreement by the Company, or (F) failure of any successor or assignee to the Company to assume this Agreement. 

In no event shall you have the right to resign for any of the reasons listed in subparagraph (ii) above and thereby trigger an
Involuntary Termination unless (i) you first notify the Corporation in writing of the existence of the relevant event or transaction constituting grounds for such an Involuntary Termination within ninety (90) days after the occurrence of
such event or transaction and (b) the Corporation fails to remedy the event or transaction constituting grounds for such Involuntary Termination within a reasonable cure period of at least thirty (30) days after receipt of such notice.

 Option means any option granted you to purchase shares of Common Stock under the Plan or other arrangement which is outstanding at
the time of the Change in Control (or, if earlier, upon the Company’s termination of your employment during the Pre-Closing Period ) or upon your Involuntary Termination following such Change in Control.  

  
 Page 4 

 Equity Award Parachute Payment means, with respect to any Equity Award, the portion of
that Equity Award deemed to be a parachute payment under Code Section 280G and the Treasury Regulations issued thereunder. The portion of such Equity Award which is categorized as an Equity Award Parachute Payment will be calculated in
accordance with the valuation provisions established under Code Section 280G and the applicable Treasury Regulations.  

Other Parachute Payment means any payments in the nature of compensation (other than your Equity Award Parachute Payment and any other
Change in Control Severance Benefits to which you become entitled under Part Two of this letter agreement) which are made to you in connection with the Change in Control and which accordingly qualify as parachute payments within the meaning of Code
Section 280G(b)(2) and the Treasury Regulations issued thereunder.  
 Parachute Payment means (i) any Change in
Control Severance Benefits provided you under Part Two of this letter agreement which is deemed to constitute a parachute payment within the meaning of Code Section 280G(b)(2) and the Treasury Regulations issued thereunder and (ii) any
Equity Award Parachute Payment.  
 Plan means (i) the Company’s 1998 Equity Incentive Plan, as amended or restated
from time to time, and (ii) any other stock incentive plan implemented or established by the Company.  
 Pre-Closing
Period means the period commencing with the Company’s execution of the definitive agreement for a Change in Control transaction and ending upon the earlier to occur of (i) the closing of the Change in Control contemplated by
such definitive agreement, or (ii) the termination of such definitive agreement without the consummation of the contemplated Change in Control. 

Present Value means the value, determined as of the date of the Change in Control, of any payment in the nature of compensation to
which you become entitled in connection with the Change in Control or your subsequent Involuntary Termination, including (without limitation) the Equity Award Parachute Payment and the additional Change in Control Severance Benefits to which you
become entitled under Part Two of this letter agreement. The Present Value of each such payment will be determined in accordance with the provisions of Code Section 280G(d)(4), utilizing a discount rate equal to one hundred twenty percent
(120%) of the applicable Federal rate in effect at the time of such determination, compounded semi-annually to the effective date of the Change in Control. 

Separation from Service means the cessation of your Employee status and shall be deemed to occur at such time as the level of the bona
fide services you are to perform in Employee status (or as a consultant or other independent contractor) permanently decreases to a  

  
 Page 5 

 
level that is not more than twenty percent (20%) of the average level of services you rendered in Employee status during the immediately preceding thirty-six (36) months (or such
shorter period for which you may have rendered such service). Any such determination as to Separation from Service, however, shall be made in accordance with the applicable standards of the Treasury Regulations issued under Section 409A of the
Code. 
 For such purpose, you will be deemed to continue in “Employee” status for so long as you remain in the employ of one or
more members of the Employer Group, subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance. “Employer Group” means the Company and any other corporation or
business controlled by, controlling or under common control with, the Company, as determined in accordance with Sections 414(b) and (c) of the Code and the Treasury Regulations thereunder, except that in applying Sections 1563(1), (2) and
(3) for purposes of determining the controlled group of corporations under Section 414(b), the phrase “at least 50 percent” shall be used instead of “at least 80 percent” each place the latter phrase appears in such
sections and in applying Section 1.414(c)-2 of the Treasury Regulations for purposes of determining trades or businesses that are under common control for purposes of Section 414(c), the phrase “at least 50 percent” shall be used
instead of “at least 80 percent” each place the latter phrase appears in Section 1.4.14(c)-2 of the Treasury Regulations. 

Specified Employee means a “key employee” (within the meaning of that term under Code Section 416(i)) who is subject to
the delayed payment provisions of subparagraph (ii) of Paragraph 1 of Part Four. Accordingly, if you are at any time during the twelve (12)-month period ending on the last day of any calendar year: 

(i) an officer of the Company whose annual compensation is greater than the compensation limit in Section 416(i)(1)(A)(i)
of the Code, provided that no more than fifty officers of the Company shall be determined to be Specified Employees as of the relevant determination date; 

(ii) a five percent owner of the Company; or 

(iii) a one percent owner of the Company whose annual compensation from the Company is more than $150,000. 

then you will be considered a Specified Employee for purposes of the Program for the twelve (12)-month period beginning on the April 1 of
the following calendar year and ending on the March 31 of the next year thereafter. 
 Termination for Cause means the
termination of your employment for any of the following reasons: (i) your conviction of a felony or your commission of any act of personal  

  
 Page 6 

 dishonesty involving the property or assets of the Company intended to result in your financial enrichment,
(ii) your material breach of one or more of your obligations under your Proprietary Information and Inventions Agreement with the Company or your unauthorized use or disclosure of any material trade secrets or other material confidential
information of the Company or any affiliate, (iii) any intentional misconduct on your part which has a materially adverse effect upon the Company’s business or reputation, (iv) your failure to perform the major duties, functions and
responsibilities of your executive position with the Company, (v) your material breach of any of your fiduciary obligations as an officer of the Company or (vi) your intentional and knowing participation in the preparation or release of
false or materially misleading financial statements relating to the Company’s operations and financial condition or your intentional and knowing submission of any false or erroneous certification required of you under the Sarbanes-Oxley Act of
2002 or any securities exchange on which shares of the Common Stock are at the time listed for trading. However, prior to any termination of your employment for any of the reasons specified in clauses (ii) through (v), the Company shall give
you written notice of the actions or omissions deemed to constitute the grounds for a Termination for Cause, and you shall have a period of not less than thirty (30) days in which to cure the specified default in performance and thereby remedy
the actions or omissions which would otherwise constitute grounds for a Termination for Cause. 
 PART TWO — CHANGE IN CONTROL
BENEFITS 
 Should your employment with the Company terminate by reason of an Involuntary Termination within twelve (12) months
after a Change in Control, or should your employment be unilaterally terminated by the Company during the Pre-Closing Period for any reason other than a Termination for Cause, then you will become entitled to receive the applicable Change in Control
Severance Benefits provided under this Part Two, provided and only if you execute and deliver to the Company, within twenty-one (21) days after the date of your termination of employment, a general release (substantially in the form of attached
Exhibit A) which becomes effective under applicable law (the “Required Release”) and pursuant to which you release the Company and its officers, directors, stockholders, employees and agents from any and all claims you may otherwise have
with respect to the terms and conditions of your employment with the Company and the termination of that employment. In no event, however, shall such release cover any claims, causes of action, suits, demands or other obligations or liabilities
relating to: 
 (a) any payments, benefits or indemnification to which you are or become entitled pursuant to the provisions
of this Agreement (including, without limitation, the severance benefits provided under this Part Two and the continued indemnification coverage under Paragraph 2 of Part Four of this Agreement); and 

  
 Page 7 

 (b) any claims for workers’ compensation benefits under any of the
Company’s workers’ compensation insurance policy or fund. 
 The Change in Control Severance Benefits provided under this Part Two
shall be in lieu of any other severance benefits to which you might otherwise become entitled under any other severance plan, program or arrangement of the Company upon a termination of your employment either during the Pre-Closing Period or within
twelve (12) months following a Change in Control. 
 1. Accelerated Vesting. 

Each outstanding Equity Award which you hold at the time of your Involuntary Termination or at any earlier termination of your employment by
the Company during the Pre-Closing Period other than a Termination for Cause, to the extent that Equity Award is not otherwise vested and exercisable for all the shares of Common Stock or other securities at the time subject to that Equity Award,
will immediately vest and become exercisable for all the covered shares or share equivalents and may be exercised for any or all of those shares or share equivalents as fully vested shares, and any such Equity Awards that are subject to a right of
repurchase, right of forfeiture, or similar right, shall be released from such right and shall be fully vested. Each such accelerated Equity Award will remain so exercisable until the earlier of (i) the expiration of the applicable term
of such Equity Award or (ii) the post-service exercise period specified in the agreement evidencing your Equity Award. Any Equity Awards not exercised prior to the expiration of the applicable post-service exercise period will terminate and
cease to remain exercisable for any of the covered shares or share equivalents. 
 2. Severance Payment. 

(a) In the event your employment terminates pursuant to an Involuntary Termination within twelve (12) months following a Change in
Control, the Company will make a lump-sum cash severance payment to you, in an amount equal to one (1.0) times the sum of your annual rate of Base Salary and Average Bonus (the “Severance Payment”). The Severance Payment shall made to
you within five (5) business days after the date your Required Release becomes effective under applicable law but no later than March 15 of the year following the Change in Control, and shall be subject to the Company’s collection of
all applicable withholding taxes, and you will only be paid the amount remaining after such withholding taxes have been collected. 
 (b) In
the event your employment is involuntarily terminated by the Company during the Pre-Closing Period for any reason other than a Termination for Cause, you will subsequently become entitled to the Severance Payment upon the closing of the Change in
Control, provided and only if that Change in Control is in fact consummated prior to the expiration of the Pre-Closing Period. The Company will make such lump-sum cash Severance 

  
 Page 8 

 
Payment to you, within five (5) business days following the later of (i) the date your Required Release becomes effective under applicable law or (ii) the effective date of the
Change in Control but no later than March 15 of the year following the Change in Control. The Severance Payment shall be subject to the Company’s collection of all applicable withholding taxes, and you will only be paid the amount
remaining after such withholding taxes have been collected. In no event, however, will you become entitled to all or any portion of the Severance Payment if the Change in Control is not consummated prior to the expiration of the Pre-Closing Period.

 3. Continued Health Care Coverage. 

Should you elect under Code Section 4980B to continue health care coverage under the Company’s group health plan for yourself, your
spouse and your eligible dependents following your Involuntary Termination or any earlier termination of your employment by the Company during the Pre-Closing Period other than a Termination for Cause, then the Company shall provide such continued
health care coverage for you and your spouse and other eligible dependents at its sole cost and expense. Such health care coverage at the Company’s expense shall continue until the earliest of (i) the expiration of the twelve
(12) month period measured from the date of your Involuntary Termination or any earlier termination of your employment by the Company during the Pre-Closing Period if you have more than five (5) years of service to the Company measured at
the time of your qualified termination, or the expiration of the six (6) month period measured from the date of your Involuntary Termination or any earlier termination of your employment by the Company during the Pre-Closing Period if you have
less than five (5) years of service to the Company, (ii) the first date you are covered under another employer’s heath benefit program which provides substantially the same level of benefits without exclusion for pre-existing medical
conditions or (iii) the date the definitive agreement for the Change in Control is terminated without consummation of that Change in Control prior to the expiration of the Pre-Closing Period. Should the Company’s provision of such
continued health care coverage result in the recognition of taxable income (whether for federal, state or local income tax purposes) by you or your spouse or other eligible dependent, then each of you will be responsible for the payment of the
income and employment tax liability resulting from such coverage, and the Company will not provide any tax gross-up payments to you (or any other person) with respect to such tax liability. 

  
 Page 9 

 PART THREE — LIMITATION ON BENEFITS 

1. Benefit Limit. 
 The
amount of the Change in Control Severance Benefits otherwise due you under Part Two of this Agreement shall be reduced to the extent necessary to assure that the Present Value of the Parachute Payment attributable to those Change in Control
Severance Benefits does not exceed the greater of the following dollar amounts (the “Benefit Limit”): 

- the dollar amount equal to (i) 2.99 times your Average Annual Compensation less (ii) the aggregate Present Value of
the Equity Award Parachute Payment and any Other Parachute Payments to which you may be entitled, or 
 - the greatest
after-tax amount of Change in Control Severance Benefits which can be paid to you under Part Two after taking into account any excise tax imposed under Code Section 4999 on those payments, the Equity Award Parachute Payment and any Other
Parachute Payments to which you might be entitled. 
 The Equity Award Parachute Payment shall also be subject to the Benefit Limit. 

2. Benefit Reduction. 

(a) To the extent the aggregate Present Value, measured as of the Change in Control, of (i) the Equity Award Parachute Payment (or
installments thereof) plus (ii) the Parachute Payment attributable to your other Change in Control Severance Benefits under Part Two of the Agreement would, when added to the Present Value of all of your Other Parachute Payments, exceed the
Benefit Limit, then the following reductions shall be made to the Change in Control Severance Benefits to which you are otherwise entitled under Part Two of this Agreement and your Equity Awards, to the extent necessary to assure that such Benefit
Limit is not exceeded: 
 first, the dollar amount of the Severance Payment to which you would otherwise be entitled
shall be reduced, and 
 then the number of shares or share equivalents which would otherwise be purchasable under
your Equity Awards shall be reduced (based on the amount of the Equity Award Parachute Payment attributable to each such Equity Award) to the extent necessary to eliminate such excess, with the actual Equity Awards to be so reduced to be determined
by you. 
 (b) In the event your employment is terminated by the Company during the Pre-Closing Period for any reason other than a
Termination for Cause, the Benefit Limit shall be calculated in good faith first at the time of such termination, with such calculation to be based upon the probability of the consummation of the contemplated Change in Control within the Pre-Closing
Period, and any benefit reduction required by Paragraph 2 of this Part Three on the basis of such good-faith calculation shall be applied at that time. The Benefit Limit shall be recalculated in accordance with this Part Three as soon as
administratively practicable following the expiration of the Pre-Closing Period. To the extent any Equity Awards are reduced and terminated in connection with 

  
 Page 10 

 
the initial calculation made at the time of your termination of employment, those Equity Awards will not be subsequently restored in connection with the re-calculation of the Benefit Limit
following the expiration of the Pre-Closing Period, even if those terminated Equity Awards could have otherwise fallen within the Benefit Limit as so re-calculated. 

3. Resolution Procedures. 

In the event there is any disagreement between you and the Company as to whether one or more payments to which you become entitled in
connection with the Change in Control or your subsequent Involuntary Termination constitute Parachute Payments, Equity Award Parachute Payments or Other Parachute Payments or as to the determination of the Present Value thereof, such dispute will be
resolved as follows: 
 (i) In the event the Treasury Regulations under Code Section 280G (or applicable judicial
decisions) specifically address the status of any such payment or the method of valuation therefor, the characterization afforded to such payment by the Regulations (or such decisions) will, together with the applicable valuation methodology, be
controlling. 
 (ii) In the event Treasury Regulations (or applicable judicial decisions) do not address the status of any
payment in dispute, the matter will be submitted for resolution to the Independent Auditors. The resolution reached by the Independent Auditors will be final and controlling; provided, however, that if in the judgment of the
Independent Auditors, the status of the payment in dispute can be resolved through the obtainment of a private letter ruling from the Internal Revenue Service, a formal and proper request for such ruling will be prepared and submitted by the
Independent Auditors, and the determination made by the Internal Revenue Service in the issued ruling will be controlling. All expenses incurred in connection with the retention of the Independent Auditors and (if applicable) the preparation and
submission of the ruling request shall be shared equally by you and the Company. 
 (iii) In the event Treasury Regulations
(or applicable judicial decisions) do not address the appropriate valuation methodology for any payment in dispute, the Present Value thereof will, at the Independent Auditor’s election, be determined through an independent third-party
appraisal, and the expenses incurred in obtaining such appraisal shall be shared equally by you and the Company. 

  
 Page 11 

 PART FOUR — MISCELLANEOUS 

1. Special Payment Provisions. Notwithstanding any provision in this letter agreement to the contrary, the following special provisions
shall govern the payment date of your Severance Payment in the event that payment is deemed to constitute an item of deferred compensation under Section 409A of the Code: 

(i). The Severance Payment will not be made at any time prior to the date of your Separation from Service or (in the event of a
unilateral termination of your employment during the Pre-Closing Period) the effective date of the Change in Control. 
 (ii)
If the payment date for your Severance Payment is tied to your Separation from Service, then in no event will the Severance Payment be made prior to the earlier of (i) the first day of the seven (7)-month period measured from the
date of your Separation from Service or (ii) the date of your death, if you are deemed at the time of such Separation from Service to be a Specified Employee and such delayed commencement is otherwise required in order to avoid a prohibited
distribution under Code Section 409A(a)(2). Upon the expiration of the applicable deferral period, the Severance Payment will be made in a lump sum on the first day of the seventh (7th) month after the date of your Separation from Service,
or if earlier, the first day of the month immediately following the date the Company receives proof of your death. 
 (iii)
Should your Severance Payment be deferred pursuant to the foregoing provisions of this Paragraph 1, then you shall be entitled to interest on your deferred Severance Payment for the period that payment is delayed by reason of subparagraph
(ii) above, , with such interest to accrue at the prime rate in effect from time to time during that period and to be paid in a lump sum upon the expiration of the deferral period. 

2. Continued Indemnification. The indemnification provisions for Officers and Directors under the Company’s bylaws, the Directors
and Officers Liability Insurance Policy (if any) and any Indemnification Agreement between you and the Company shall (to the maximum extent permitted by law) be extended to you during the period following your resignation or termination of
employment for any reason (other than a Termination for Cause), whether or not in connection with a Change in Control, with respect to all matters, events or transactions occurring or effected during your period of employment with the Company. 

3. No Mitigation Duty. The Company shall not be entitled to set off any of the following amounts against the Change in Control
Severance Benefits to which you may become entitled under Part Two of this Agreement: (i) any amounts which you may subsequently  

  
 Page 12 

 
earn through other employment or service following his termination of employment with the Company or (ii) any amounts which you might have potentially earned in other employment or service
had you sought such other employment or service. 
 4. Death. Should you die before your receive the full amount of payments and
benefits to which you may become entitled under this Agreement, then the balance of such payments shall be made, on the due dates hereunder had you survived, to the executors or administrators of your estate. Should you die before you exercise all
your outstanding Equity Awards as accelerated hereunder, then such Equity Awards may be exercised, within the applicable exercise period following your death, by the executors or administrators of your estate or by the persons to whom those Equity
Awards are transferred pursuant to your will or in accordance with the laws of inheritance. In no event, however, may any such Equity Award be exercised after the specified expiration date of the option term. 

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of, and shall be binding upon, (i) the
Company and its successors and assigns, including any successor entity by merger, consolidation or transfer of all or substantially all of the Company’s assets (whether or not such transaction constitutes a Change in Control), and
(ii) you, the personal representative of your estate and your heirs and legatees.  
 6. General Creditor Status. The
benefits to which you may become entitled under Part Two of this Agreement shall be paid, when due, from the Company’s general assets. No trust fund, escrow arrangement or other segregated account shall be established as a funding vehicle for
such payments. Your right (or the right of the executors or administrators of your estate) to receive such benefits shall at all times be that of a general creditor of the Company and shall have no priority over the claims of other general
creditors. 
 7. Amendment and Termination. 

(a) This letter agreement may only be amended by written instrument signed by you and an authorized officer of the Company. This letter
agreement shall terminate upon a Separation from Service other than (i) by reason of an Involuntary Termination within twelve (12) months after a Change in Control, or (ii) a unilateral termination by the Company during the
Pre-Closing Period solely for a Termination for Cause. 
 (b) Once a Change in Control has been effected, this letter agreement may not be
terminated at any time prior to the expiration of the twelve (12) month period following the effective date of that Change of Control except by voluntary termination, and no subsequent termination of this letter agreement except by voluntary
termination shall adversely affect your right to receive any benefits to which you may have previously become entitled hereunder in connection with your Involuntary Termination following that Change in Control. 

  
 Page 13 

 8. Termination for Cause. In the event of your Termination for Cause or your resignation
under circumstances which would otherwise constitute grounds for a Termination for Cause, the Company will only be required to pay you (i) any unpaid compensation earned for services previously rendered through the date of such termination and
(ii) any accrued but unpaid vacation benefits or sick days, and no benefits will be payable to you under Part Two of this letter agreement. 

9. Governing Law/Other Agreements. This letter agreement is to be construed and interpreted under the laws of the State of California.
This letter agreement supersedes all prior agreements between you and the Company relating to the subject of severance benefits payable upon a change in control or ownership of the Company, and you will not be entitled to any other severance
benefits upon such a termination other than those that are provided in this letter agreement. 
 10. At Will Employment. Nothing in
this letter agreement is intended to provide you with any right to continue in the employ of the Company (or any subsidiary) for any period of specific duration or interfere with or otherwise restrict in any way your rights or the rights of the
Company (or any subsidiary), which rights are hereby expressly reserved by each, to terminate your employment at any time and for any reason, with or without cause. 

  
 Page 14 

 Please indicate your agreement with the foregoing terms and conditions of your change in control
severance package by signing the Acceptance section of the enclosed copy of this letter and returning it to the Company. 
  

			
		 	Very truly yours,
		
		 	ACTUATE CORPORATION
		
	By:	 	  

		
	Title:	 	  

 ACCEPTANCE 

I hereby agree to all the terms and provisions of the foregoing letter agreement governing the special benefits to which I may become entitled
in the event my employment should terminate under certain prescribed circumstances following a substantial change in control or ownership of the Company. 
  

			
	Signature:	 	  

		
	Dated:	 	  

		
	Address	 	  

		
		 	  

  
 Page 15 

 EXHIBIT A 

 RELEASE AND WAIVER OF CLAIMS 

In consideration of the severance payments and other benefits to which I have become entitled, pursuant to that certain letter agreement
between Actuate Corporation, a Delaware corporation (the “Company”), and myself dated                      (the “Severance
Agreement), in connection with the termination of my employment on this date, I,
                                        ,
hereby furnish the Company with the following release and waiver (“Release and Waiver”). 
 I hereby release and forever discharge
the Company, its officers, directors, agents, employees, stockholders, successors, assigns and affiliates from any and all claims, liabilities, demands, causes of action, costs, expenses, attorney fees, damages, indemnities and obligations of every
kind and nature, in law, equity or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed, arising from or relating to my employment with the Company and the termination of that employment, including (without limitation)
claims of wrongful discharge, emotional distress, defamation, fraud, breach of contract, breach of the covenant of good faith and fair dealing, discrimination claims based on sex, age, race, national origin, disability or any other basis under Title
VII of the Civil Rights Act of 1964, as amended, the California Fair Employment and Housing Act, the Federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”), the Americans with Disability Act, contract claims, tort
claims, and wage or benefit claims, including (without limitation) claims for salary, bonuses, commissions, stock grants, stock options, vacation pay, fringe benefits, severance pay or any other form of compensation (other than the payments and
benefits to which I am entitled under the Severance Agreement, my vested rights under the Company’s Section 401(k) Plan and any worker’s compensation benefits under any Company workers’ compensation insurance policy or fund).

 In releasing claims unknown to me at present, I am waiving all rights and benefits under Section 1542 of the California Civil
Code, and any law or legal principle of similar effect in any jurisdiction: “A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known
by him must have materially affected his settlement with the debtor.” 
 This Release and Waiver does not pertain to any claims
which may subsequently arise in connection with the Company’s default in any of its payment obligations under the Severance Agreement or its indemnification obligations to me thereunder. 

I acknowledge that, among other rights subject to his Release and Waiver, I am hereby waiving and releasing any rights I may have under ADEA,
that this release and waiver is knowing and voluntary, and that the consideration given for this release and waiver is in addition to anything of value to which I was already entitled as an executive of the Company. I further acknowledge that I have
been advised, as required by the Older Workers Benefit Protection Act, that: (a) the release and waiver granted herein does not relate to claims which may arise after this release and waiver is executed; (b) I have the right to consult
with an attorney prior to executing this release and waiver (although I may choose voluntarily not to do so); and if I am 

 over 40 years old upon execution of this (c) I have twenty-one (21) days from the date of termination
of my employment with the Company in which to consider this release and waiver (although I may choose voluntarily to execute this release and waiver earlier); (d) I have seven (7) days following the execution of this release and waiver to
revoke my consent to this release and waiver; and (e) this release and waiver shall not be effective until the seven (7)-day revocation period has expired. 
  

													
	Date:	 	  
	 		 		 		 		 	  

		 		 		 		 		 		 	EXECUTIVE

  
 Page 3CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of
this document have been redacted and have been separately filed with the Commission.

 

Exhibit No. 10.1

 

LICENSE
AGREEMENT

 

Dated as of June 23, 2014

 

by and between

 

Ligand Pharmaceuticals Incorporated

 

and

 

TG Therapeutics, Inc.

 

    	 

    	 

    

 

LICENSE
AGREEMENT

 

THIS LICENSE AGREEMENT
(the “Agreement”) is dated as of June 23, 2014 (the “Effective Date”) by and between Ligand
Pharmaceuticals Incorporated, a Delaware corporation organized having its place of business at 11119 North Torrey Pines Road, Suite
200, La Jolla, California 92037 (including its successors and permitted assigns, “Licensor”), and TG Therapeutics,
Inc., a Delaware corporation with its place of business at 3 Columbus Circle, 15th Floor, New York, New York 10019 (including its
successors and permitted assigns and all of its Affiliates, “TGTX”). TGTX, on the one hand, and Licensor, on
the other hand, shall each be referred to herein as a “Party” or, collectively, as the “Parties.”

 

RECITALS:

 

WHEREAS, TGTX
is engaged in the research, development, manufacturing and commercialization of pharmaceutical products, and TGTX is interested
in developing and commercializing products containing or comprising the Compounds; and

 

WHEREAS, TGTX
desires to license from Licensor and Licensor wishes to license to TGTX, on an exclusive basis, the right to use, develop and commercialize
Licensor Technology in and for a defined field of use.

 

NOW, THEREFORE,
in consideration of the foregoing and of the various promises and undertakings set forth herein, the Parties agree as follows:

 

ARTICLE
I

DEFINITIONS

 

Unless otherwise specifically
provided herein, the following terms shall have the following meanings:

 

1.1        “Affiliate”
means a Person or entity that controls, is controlled by or is under common control with a Party, but only for so long as such
control exists. For the purposes of this Section 1.1, the word “control” (including, with correlative meaning,
the terms “controlled by” or “under common control with”) means the actual power, either
directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether
by the ownership of at least 50% of the voting stock of such entity, or by contract or otherwise.

 

1.2       “Calendar
Quarter” means each three month period commencing January 1, April 1, July 1 or October 1, provided
however that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full
Calendar Quarter thereafter, and (b) the last Calendar Quarter of the Term shall end upon the termination or expiration of
this Agreement.

 

1.3       “Calendar
Year” means the period beginning on the 1st of January and ending on the 31st of December of the
same year, provided however that (a) the first Calendar Year of the Term shall commence on the Effective Date and end on December 31
of the same calendar year as the Effective Date, and (b) the last Calendar Year of the Term shall commence on January 1
of the Calendar Year in which this Agreement terminates or expires and end on the date of termination or expiration of this Agreement.

 

    	 

    	 

    

 

 

1.4       “Combination
Product” means a product (a) containing a Licensed Product together with one or more other active ingredients, or (b)
with one or more products, devices, pieces of equipment or components, but sold for an integrated price (e.g., with the purchase
of one product the customer gets a coupon for the other) or for a single price.

 

1.5       “Commercialization”
or “Commercialize” means any and all activities undertaken at any time for a particular Licensed Product
and that relate to the manufacturing, marketing, promoting, distributing, importing or exporting for sale, offering for sale, and
selling of the Licensed Product, and interacting with Regulatory Authorities regarding the foregoing.

 

1.6       “Commercially
Reasonable Efforts” means, with respect to the efforts to be expended by a Party or such Party’s applicable Affiliate
with respect to any objective, such reasonable, diligent, and good faith efforts normally used to accomplish a similar objective
under similar circumstances by a similarly-situated company. Commercially Reasonable Efforts will not mean that a Party commits
that it or such Party’s applicable Affiliate will actually accomplish the applicable task.

 

1.7       “Compounds”
means Licensor’s proprietary Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors set forth on Schedule 1
and any other salts, solvates, esters, metabolites, hydrates, intermediates, stereoisomers, polymorphs, and derivatives of such
compounds, and any other IRAK-4 inhibitors discovered or developed by Licensor during the first six months after the Effective
Date and any other salts, solvates, esters, metabolites, hydrates, intermediates, stereoisomers, polymorphs, and derivatives of
such compounds.

 

1.8       “Controlled”
means, with respect to (a) Patent Rights, (b) Know-How or (c) biological, chemical or physical material, that a
Party or one of its Affiliates owns or has a license or sublicense to such Patent Rights, Know-How or material (or in the case
of material, has the right to physical possession of such material) and has the ability to grant a license or sublicense to, or
assign its right, title and interest in and to, such Patent Rights, Know-How or material as provided for in this Agreement without
violating the terms of any agreement or other arrangement with any Third Party.

 

1.9        “Covered”
means, with respect to a Licensed Product, that the manufacturing, importing, using, selling, or offering for sale of such
Licensed Product would, but for ownership of or a license granted hereunder under Licensor’s relevant Patent Rights, infringe
a Valid Claim of Licensor’s relevant Patent Rights in the country in which the activity occurs.

 

1.10       “Development”
or “Develop” means, with respect to a Licensed Product, the performance of all preclinical and clinical development
(including, without limitation, toxicology, pharmacology, test method development and stability testing, process development, formulation
development, quality control development, statistical analysis), clinical trials, and manufacturing and regulatory activities that
are required to obtain Regulatory Approval of such Licensed Product.

 

1.11       “EMA”
means the European Medicines Agency or any successor agency.

 

1.12       “European
Commission” means the authority within the European Union that has the legal authority to grant Regulatory Approvals
in the European Union based on input received from the EMA or other competent Regulatory Authorities.

 

    	 

    	 

    

 

1.13       “FDA”
means the United States Food and Drug Administration, or a successor federal agency thereto.

 

1.14       “Field”
means all prophylactic, palliative, therapeutic or diagnostic uses in humans.

 

1.15       “First
Commercial Sale” means, with respect to a Licensed Product in any country, the first commercial transfer or disposition
for value of such Licensed Product in such country to a Third Party by TGTX, an Affiliate of TGTX or a Sublicensee after Regulatory
Approval therefor has been obtained in such country.

 

1.16       “GAAP”
means United States generally accepted accounting principles.

 

1.17       “Governmental
Body” means any: (a) nation, principality, state, commonwealth, province, territory, county, municipality, district
or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental
or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch,
office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and
any court or other tribunal); (d) multi-national or supranational organization or body; or (e) individual, entity, or
body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or
taxing authority or power of any nature.

 

1.18       “Know-How”
means any scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form
whatsoever, that is not in the public domain or otherwise publicly known, including, without limitation, discoveries, inventions,
trade secrets, databases, practices, protocols, regulatory filings, methods, processes, techniques, software, works of authorship,
plans, concepts, ideas, biological and other materials, reagents, specifications, formulations, formulae, data (including, but
not limited to, pharmacological, biological, chemical, toxicological, clinical and analytical information, quality control, trial
and stability data), case reports forms, data analyses, reports, studies and procedures, designs for experiments and tests and
results of experimentation and testing (including results of research or development), summaries and information contained in submissions
to and information from ethical committees, the FDA or other Regulatory Authorities, and manufacturing process and development
information, results and data, whether or not patentable, all to the extent not claimed or disclosed in a patent or pending patent
application. The fact that an item is known to the public shall not be taken to exclude the possibility that a compilation including
the item, and/or a development relating to the item, is (and remains) not known to the public. “Know-How” includes
any rights including copyright, moral, trade-secret, database or design rights protecting such Know-How. “Know-How”
excludes Patent Rights.

 

1.19       “Indication”
means a generally acknowledged disease or condition, a significant manifestation of a disease or condition, or symptoms associated
with a disease or condition or a risk for a disease or condition, which a Licensed Product is intended to address; provided, however,
that with respect to the each of the Product Milestone Events, if each of the first two Indications for which a particular Product
Milestone Event has been achieved both involve oncology, no further indication shall (with regard to such particular Product Milestone
Event) be deemed to be an Indication unless the further indication is for a non-oncology indication. For the avoidance of doubt,
in the event the first two Indications for which a particular Product Milestone Event has been achieved both involve oncology,
no additional milestones shall be due under Section 5.2 for any subsequent, oncology-related Indication.

 

    	 

    	 

    

 

1.20       “Law”
or “Laws” means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having
the binding effect of law of any Governmental Body.

 

1.21       “Licensed
Product” means any pharmaceutical product, in any dosage form, preparation, composition, formulation, presentation or
package configuration, that is Commercialized or undergoing research or preclinical or clinical Development that contains or comprises,
in part or in whole, a Compound. For clarity: if a product is described by the foregoing sentence it is a “Licensed Product”
for all purposes hereof whether or not it is Covered and whether or not the manufacturing, importing, using, selling, or offering
for sale of such product would, but for a license granted under this Agreement under the Licensor Technology, infringe any Licensor
Technology in the country in which the activity occurs.

 

1.22       “Licensor
Know-How” means any and all Know-How that (a) is Controlled by Licensor or any of its Affiliates as of the Effective
Date or at any time thereafter during the Term and (b) pertains directly and particularly to the Compounds and (c) is from time
to time expressly identified in writing by Licensor to TGTX as constituting Licensor Know-How. For clarity: any and all Know-How
which Licensor determines, in its reasonable discretion, not to so expressly identify as being within the definition of Licensor
Know-How shall not constitute Licensor Know-How. The Licensor Know-How shall include, but not be limited to, the Know-How listed
on Schedule 2 hereto.

 

1.23       “Licensor
Patents” means all Patent Rights that are Controlled by Licensor or any of its Affiliates as of the Effective Date or
at any time thereafter during the Term and that pertain directly and particularly to the Compounds, other inhibitors of IRAK-4
and/or IRAK-4 inhibition. The Licensor Patents shall include, but not be limited to, all Patent Rights set forth on Schedule
3 hereto.

 

1.24       “Licensor
Technology” means the Licensor Patents and the Licensor Know-How.

 

1.25       “Major
Market” means any of the (a) United States, (b) the European Union (either in its entirety or including at least one
Major Market EU Country, as determined by TGTX in its sole discretion), or (c) Japan.

 

1.26       “Major
Market EU Country” means any of France, Germany and the United Kingdom.

 

1.27       “NDA”
means a New Drug Application submitted pursuant to the requirements of the FDA, as more fully defined in 21 U.S. CFR § 314.3
et seq., a Biologics License Application submitted pursuant to the requirements of the FDA, as more fully defined in 21 U.S. CFR
§ 601, and any equivalent application submitted in any country, including a European Marketing Authorization Application,
together, in each case, with all additions, deletions or supplements thereto.

 

1.28       “NDA
Approval” means the receipt of notice from the relevant US Regulatory Authority that an NDA for a Licensed Product has
met all the criteria for marketing approval.

 

1.29       “Net
Sales” means the gross amount invoiced or otherwise charged by TGTX, its Affiliates and Sublicensees to unrelated Third
Parties for a Licensed Product, less:

 

		(a)	Normal and customary trade, quantity, cash and discounts and credits allowed and taken;

 

    	 

    	 

    

 

		(b)	Discounts, refunds, rebates, chargebacks, retroactive price adjustments, and any other allowances
given and taken which effectively reduce the net selling price (other than such which have already diminished the gross amount
invoiced such as those outlined in Section 1.29(a) above), including, without limitation, Medicaid rebates, institutional rebates
or volume discounts;

 

		(c)	Product returns and allowances;

 

		(d)	Administrative fees paid to group purchasing organizations (e.g., Medicare) and government-mandated
rebates;

 

		(e)	Shipping, handling, freight, postage, insurance and transportation charges, but all only to the
extent included as a separate line item in the gross amount invoiced;

 

		(f)	Any tax, tariff or duties imposed on the production, sale, delivery or use of the Licensed Product,
including, without limitation, sales, use, excise or value added taxes and customs and duties, but all only to the extent included
as a separate line item (e.g., “taxes”) in the gross amount invoiced; and

 

		(g)	Bad debt actually written off during the accounting period (provided, that any bad debt write-off
so taken which is later reversed shall be added back to Net Sales in the accounting period in which the reversal occurs).

 

Notwithstanding the
foregoing, amounts invoiced by TGTX and its Affiliates and Sublicensees for sales of Licensed Products among TGTX and its Sublicensees
and their respective Affiliates for resale shall not be included in the computation of Net Sales.

 

In the event that a
Licensed Product is commercialized as part of a Combination Product for a single price, then for the purpose of determining Net
Sales the gross amount invoiced or otherwise charged by TGTX for such Licensed Product shall be calculated by multiplying the sales
price of such Combination Product by the fraction A/(A+B) where A is the fair market value of the Licensed Product and B is the
fair market value of the other product(s) in the Combination Product; and the applicable deductions from the gross amount invoiced
or otherwise charged by TGTX shall be allocated between the Licensed Product and the other product(s) in the Combination Product
in the same proportion.

 

1.30        “Patent
Right” means: (a) an issued or granted patent, including any extension, supplemental protection certificate, registration,
confirmation, reissue, reexamination, extension or renewal thereof; (b) a pending patent application, including any continuation,
divisional, continuation-in-part, substitute or provisional application thereof; and (c) all counterparts or foreign equivalents
of any of the foregoing issued by or filed in any country or other jurisdiction, provided however that, with respect to items (b)
and (c), no patent application shall be pending for a period of greater than seven years from its actual date of filing.

 

1.31       “Person”
means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership
or other business entity, or any government or agency or political subdivision thereof.

 

    	 

    	 

    

 

 

1.32        “Phase I
Trial” means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining
the safety of and/or the metabolism and pharmacologic actions of the Licensed Product in humans, as described under 21 CFR §
312.21(a) (as hereafter modified or amended) and any of its foreign equivalents.

 

1.33       “Phase III
Trial” means a clinical trial of a Licensed Product in human patients, which trial is designed (a) to establish
that the Licensed Product is safe and efficacious for its intended use; (b) to define warnings, precautions and adverse reactions
that are associated with the Licensed Product in the dosage range to be prescribed; and (c) to be, either by itself or together
with one or more other clinical trials having a comparable design and size, the final human clinical trial in support of Regulatory
Approval of the Licensed Product, and (d) consistent with 21 CFR § 312.21(c) (as hereafter modified or amended) and any
of its foreign equivalents. Provided that, and for avoidance of doubt: any pivotal trial, which is intended to be or is in fact
used as one of the adequate and well-controlled trials for registration in any jurisdiction, shall be deemed to be a Phase III
Trial.

 

1.34       “Product
Milestone Events” means the second, third, fourth, fifth, sixth and seventh milestone events specified in Section 5.2.

 

1.35       “Regulatory
Authority” means (a) the FDA, (b) the EMA or the European Commission, or (c) any regulatory body with
similar regulatory authority over pharmaceutical or biotechnology products in any other jurisdiction anywhere in the world.

 

1.36       “Regulatory
Approval” means any and all approvals, licenses, registrations, or authorizations of the relevant Regulatory Authority,
necessary for the Development, manufacture, use, storage, import, transport and Commercialization of a given Licensed Product in
a particular country or jurisdiction. For the avoidance of doubt, Regulatory Approval outside of the United States shall include
any pricing or marketing approval needed prior to the sale of a Licensed Product in the Field.

 

1.37       “Royalty
Term” means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period from the First Commercial
Sale of a given Licensed Product in such country until the later of (a) expiry of the last-to-expire Licensor Patent containing
a Valid Claim to the Compound in such country; or (b) the 10th anniversary of the First Commercial Sale of such Licensed
Product in such country. In a country where no Licensor Patent containing a Valid Claim with respect to the Compound has ever existed
nor ever exists, the Royalty Term means on a product-by-product and country-by-country basis, the period from the First Commercial
Sale of such product in such country until the 10th anniversary of such First Commercial Sale of such product in such
country.

 

1.38       “Sales
Milestone Events” means the eighth and ninth milestone events specified in Section 5.2.

 

1.39       “Share
Value” as of a particular date means the mean average of the respective trading days’ closing sale prices of the
Shares on the Shares’ principal United States securities exchange for each of the eighteen trading days immediately preceding
such date; it being understood that any such closing sale prices shall be adjusted appropriately to reflect the occurrence of any
stock split, reverse stock split, recapitalization, reorganization or other such event.

  

    	 

    	 

    

 

1.40       “Shares”
means shares of TGTX’s common stock, par value $0.001 per share, as constituted on the Effective Date; the meaning of such
term shall be adjusted appropriately to reflect the occurrence of any stock split, reverse stock split, recapitalization, reorganization
or other such event.

 

1.41       “Sublicensee”
means a Person, other than an Affiliate of TGTX, to which TGTX (or its Affiliate) has, pursuant to Section 2.2, granted
sublicense rights under any of the license rights granted under Section 2.1. “Sublicense” shall be construed
accordingly.

 

1.42       “Tax”
or “Taxes” means any federal, state, local or foreign income, gross receipts, license, payroll, employment,
excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits,
withholding, social security, unemployment, disability, real property, personal property, sales, use, transfer, registration, value
added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any interest, penalty, or addition
thereto, whether disputed or not.

 

1.43       “Third
Party” means any Person other than Licensor, TGTX or Affiliates of either of them, or any Sublicensees.

 

1.44       “Third
Party Action” means any claim or action made by a Third Party against a Party that claims that a Licensed Product, or
its use, Development, manufacture or sale infringes such Third Party’s intellectual property rights.

 

1.45        “United
States” or “US” means the United States of America and its territories and possessions.

 

1.46       “Upfront
Shares” means 125,000 Shares.

 

1.47       “Valid
Claim” means a claim of an issued and unexpired patent which has not lapsed or been revoked, abandoned or held unenforceable
or invalid by a final decision of a court or governmental agency of competent jurisdiction, unappealable or unappealed within the
time allowed for appeal, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue,
reexamination or disclaimer or otherwise.

 

1.48       The definition
of each of the following terms is set forth in the section of the Agreement indicated below:

 

“Action”
has the meaning set forth in Section 6.5(b).

 

“Claim”
has the meaning set forth in Section 9.1.

 

“Confidential
Information” has the meaning set forth in Section 7.1.

 

“Controlling
Party” has the meaning set forth in Section 6.6(c).

 

“Development
Program” has the meaning set forth in Section 3.1.

 

“Disclosing
Party” has the meaning set forth in Section 7.1. 

 

“Generic Supply”
has the meaning set forth in Section 5.4(b).

 

    	 

    	 

    

 

 

“Indemnified
Party” has the meaning set forth in Section 9.4.

 

“Indemnifying
Party” has the meaning set forth in Section 9.4.

 

“Licensor Indemnitees”
has the meaning set forth in Section 9.1.

 

“Notice”
has the meaning set forth in Section 7.6.

 

“Publishing
Party” has the meaning set forth in Section 7.6.

 

“Receiving
Party” has the meaning set forth in Section 7.1. 

 

“Term”
has the meaning set forth in Section 10.1.

 

“TGTX Indemnitees”
has the meaning set forth in Section 9.2. 

 

ARTICLE II

LICENSES AND OTHER RIGHTS

 

2.1       Grant of
License to TGTX. Subject to the terms and conditions of this Agreement, Licensor hereby grants to TGTX and its Affiliates,
and TGTX and its Affiliates hereby accept, an exclusive (even as to Licensor), worldwide, royalty-bearing right and license (with
the right to sublicense, and to further sublicense, subject to the provisions of Section 2.2) under the Licensor Technology to
research, Develop, manufacture, have manufactured, use, import and Commercialize and have Commercialized the Licensed Products
in and for the Field. Licensor and its Affiliates grant no licenses or rights to use other than as expressly set forth herein.

 

2.2       Grant of
Sublicenses by TGTX. TGTX shall have the right, in its sole discretion, to grant Sublicenses, in whole or in part, under the
license granted in Section 2.1; provided, however, that the granting by TGTX of a Sublicense shall not relieve TGTX of any of its
obligations hereunder; and provided, further, that TGTX’s right to grant a Person a Sublicense shall be subject to TGTX including
within such Sublicense express provisions binding the Sublicensee to all of the duties, obligations, restrictions and acknowledgements
hereunder of TGTX (with Licensor being an express third-party beneficiary thereof), and stating that the Sublicense shall (except
as otherwise expressly provided in Section 10.3 or 10.4(c)) automatically terminate upon the expiration or earlier termination
of this Agreement. Notwithstanding the foregoing sentence, it is not required that a Sublicense include provisions for the Sublicensee
to pay Royalties or make milestone payments directly to Licensor or to provide royalty reports directly to Licensor. TGTX shall
ensure that all of its Sublicensees shall comply with the terms and conditions of this Agreement (as applicable to them) and TGTX
shall be and remain fully responsible for the compliance by such Sublicensees with the terms and conditions of this Agreement (as
applicable to them) as if such Sublicensees were TGTX hereunder. Except for Sublicenses as expressly allowed herein, TGTX acknowledges
that it has no right to, and agrees not to purport to, grant to anyone a sublicense under the Licensor Technology.

 

2.3       Bankruptcy
Code. All rights and licenses granted under or pursuant to this Agreement by Licensor to TGTX are, and shall otherwise be deemed
to be, for purposes of Section 365(n) of the US Bankruptcy Code, licenses of rights to “intellectual property” as defined
under Section 101 of the US Bankruptcy Code. The Parties agree that TGTX, as a licensee of such rights under this Agreement, shall
retain and may fully exercise all of its rights and elections under the US Bankruptcy Code.

 

    	 

    	 

    

 

 

2.4       Service Agreement.
The Parties acknowledge that the Parties may choose in the future to negotiate toward a research agreement in support of the Development
Program; however, neither Party shall be obligated to negotiate toward, or to enter into, such a research agreement, and in the
absence of any such definitive written research agreement Licensor shall have no obligation to assist TGTX’s research and
development.

 

ARTICLE III

DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION

 

3.1       Diligence
by TGTX. TGTX shall use Commercially Reasonable Efforts to Develop and to Commercialize at least one Licensed Product in and
for the Field in at least one Major Market. In connection therewith, TGTX shall formulate and execute a preclinical and clinical
development program to Develop one or more Licensed Products in and for the Field in at least one Major Market (the “Development
Program”).

 

3.2       No Guaranty
of Favorable Results. Licensor does not warrant that the Development Program, TGTX’s other preclinical studies and evaluation
(if any) and/or TGTX’s clinical studies (if any) will produce any particular results or any favorable results.

 

3.3       TGTX Responsibility
and Authority for Development. TGTX shall have the exclusive right, and sole responsibility and decision-making authority,
to research and Develop any Licensed Products in and for the Field and to conduct (either itself or through its Affiliates, agents,
subcontractors and/or Sublicensees) all clinical trials and non-clinical studies TGTX believes appropriate to obtain Regulatory
Approval for Licensed Products in and for the Field.

 

3.4       Commercialization.
TGTX shall have the exclusive right, and sole responsibility and decision-making authority, to Commercialize any Licensed Products
in and for the Field itself or through one or more Sublicensees or other Third Parties selected by TGTX and shall have the sole
decision-making authority and responsibility in all matters relating to the Commercialization of Licensed Products.

 

3.5       Manufacturing.
TGTX shall have the exclusive right, and sole responsibility and decision-making authority, to manufacture, at the clinical and/or
commercial stage, any Licensed Product in and for the Field itself or through one or more Sublicensees selected by TGTX.

 

3.6       Reporting
to Licensor. TGTX shall, at least once each Calendar Year, provide to Licensor an update report regarding the progress of all
research and Development efforts toward Licensed Products and regarding the progress of Commercialization of Licensed Products.

 

3.7       Right to
Subcontract of TGTX. Subject to any required compliance with Section 2.2, TGTX may exercise any of the rights or obligations
that TGTX may have under this Agreement (including, without limitation, any of the rights licensed in Section 2.1 hereof) by Sublicensing,
but any Sublicense granted or entered into by TGTX as contemplated by this Section 3.7 or any Sublicensee’s exercise or performance
of all or any portion of the rights or obligations that TGTX may have under this Agreement shall not relieve TGTX from any of its
obligations under this Agreement.

 

    	 

    	 

    

 

 

3.8       Compliance
with Law. TGTX undertakes and agrees that the conduct of the Development Program, the use of the Licensor Technology, and all
Development, manufacture and Commercialization of Licensed Products by it and its Affiliates and Sublicensees shall comply in all
material respects with all applicable international, federal, state and local laws, rules and regulations, including, but not limited
to, environmental, occupational safety/health, safety and import/export restrictions, laws, rules and regulations.

 

3.9       Costs and
Expenses. As between Licensor and TGTX, TGTX shall be solely responsible for all costs and expenses related to Development,
manufacture and Commercialization of the Licensed Products, including without limitation costs and expenses associated with all
preclinical activities and clinical trials, and all regulatory filings and proceedings relating to Licensed Product.

 

3.10       .Patent
Marking. TGTX agrees that with respect to each unit or package of Licensed Products sold in a given country, TGTX shall comply
with the customary patent marking laws and practices of such country as to the applicable Licensor Patents.

 

3.11       Trademarks.
As between Licensor and TGTX, TGTX shall have the sole authority to select trademarks for Licensed Products and shall own all such
trademarks. Licensor does not grant TGTX the right to use any trademarks of Licensor or its Affiliates.

 

ARTICLE IV

REGULATORY MATTERS

 

4.1       Regulatory
Filings. As between TGTX and Licensor, TGTX (or its applicable Affiliate) shall own and maintain all regulatory filings made
after the Effective Date for Licensed Products and all Regulatory Approvals for Licensed Products.

 

4.2       Communications
with Authorities. TGTX (or one of its Affiliates or Sublicensees) shall be responsible for and act as the sole point of contact
for communications with Regulatory Authorities in connection with the Development, Commercialization, and manufacturing of Licensed
Products. At the request of TGTX, Licensor shall make available to TGTX, at no more than a reasonable charge, a qualified representative
who shall, together with the representatives of TGTX, participate in and contribute to meetings with the Regulatory Authorities
with respect to regulatory matters relating solely to the Licensor Technology.

 

4.3       Adverse Event
Reporting. TGTX agrees to comply with any and all Laws that are applicable to it as of the Effective Date and thereafter during
the Term in connection with Licensed Product safety data collection and reporting (and, if applicable, recalls). TGTX shall provide
annually to Licensor a listing of each serious untoward medical occurrence in a patient or subject who is administered a Licensed
Product and shall, should Licensor expressly so request and TGTX approve (such approval not to be unreasonably withheld), provide
Licensor with additional detail as to such ones of such occurrences as Licensor may designate.

 

ARTICLE V

Financial Provisions

 

5.1       Upfront Fee.
TGTX becomes obligated on the Effective Date to pay Licensor the Upfront Shares in partial consideration of the rights granted
to Company under this Agreement. TGTX shall deliver to Licensor a stock certificate representing the Upfront Shares on the Effective
Date or within five business days thereafter, provided that in any event such stock certificate is delivered on or before June
30, 2014. Such stock certificate shall be unlegended except for a standard securities-law restrictive legend.

 

    	 

    	 

    

 

 

5.2       Commercial
Milestone Payments. As further partial consideration for Licensor’s grant of the rights and licenses to TGTX hereunder,
TGTX shall pay to Licensor the following one-time, non-refundable milestone payments (a) with regard to the first Licensed Product
to achieve the respective Product Milestone Event, for each of the first *
Indications for which a Licensed Product achieves the respective Product Milestone Event, and (b) upon achievement of each respective
Sales Milestone Event by TGTX or its Affiliate or Sublicensee. TGTX shall promptly, but in no event later than 15 days following
TGTX or its Affiliate’s receipt of actual knowledge of each achievement of a milestone event, notify Licensor in writing
of the achievement of such milestone event and shall pay the relevant milestone payment within 20 days thereafter. All milestone
and other Article V payments shall be paid in cash except that in the case of any achievement of the second Product Milestone Event
(Enrollment of at least 100 patients (combined) in all clinical trials for the indication), TGTX shall have the right to elect
(but only within the notice of achievement referred to in the preceding sentence, and only if such notice of achievement is not
delivered untimely) to pay any amounts owed not in the form of cash but rather in the form of a number of Shares equal to amount
owed divided by the Share Value as of the date such notice of achievement is delivered; or some portion (designated and specified
by TGTX in its discretion within such notice of achievement, which such notice of achievement is not delivered untimely) of the
amount owed in cash and the remainder in the form of a number of Shares equal to such remainder divided by the Share Value as of
the date such notice of achievement is delivered. (Any such election shall be irrevocable.) If TGTX makes such election it shall
deliver to Licensor a stock certificate representing the Shares on the date such notice of achievement is delivered or within five
business days thereafter; such stock certificate shall be unlegended except for a standard securities-law restrictive legend.

 

	Milestone Event	 	Milestone Payment	 	Total Milestone 
 Payments (if achieved 
 with three 
 Indications)	 
	First dosing of any patient in any Phase I Trial	 	* Shares	 	 	n/a	 
	Enrollment of at least 100 patients (combined) in all clinical trials for the Indication	 	$* (per Indication)	 	$	*	 
	Enrollment of first patient in first Phase III Trial	 	$* (per Indication)	 	$	*	 
	NDA filing in the United States for a Licensed Product	 	$* (per Indication)	 	$	*	 
	Regulatory Approval in the United States for a Licensed Product	 	$* (per Indication)	 	$	*	 
	Regulatory Approval in or for a Major Market EU Country for a Licensed Product	 	$* (per Indication)	 	$	*	 
	Regulatory Approval in Japan for a Licensed Product	 	$* (per Indication)	 	$	*	 
	The first time aggregate worldwide Net Sales for all Licensed Products exceeds $1,000,000,000 in any Calendar Year	 	$*	 	 	n/a	 
	The first time aggregate worldwide Net Sales for all Licensed Products exceeds $3,000,000,000 in any Calendar Year	 	$*	 	 	n/a	 

 

 

* Confidential
material redacted and filed separately with the Commission.

 

    	 

    	 

    

 

For avoidance of doubt: it is possible that the first three
Indications to achieve a particular milestone event might not be identical with the first three Indications to achieve a different
particular milestone event; this non-identity would not affect the validity of the three-time milestone event achievement for either
of the milestone events. For the avoidance of doubt, in the event the first two Indications for which a particular Product Milestone
Event has been achieved both involve oncology, no additional milestones shall be due under Section 5.2 for any subsequent, oncology-related
Indication.

 

5.3         Deemed Achievement
of Commercial Milestones. Upon achievement of any respective Product Milestone Event with regard to a particular Indication,
all “prior” milestone events shall be deemed to be thereby achieved as to such Indication; and if the milestone payment
for any such “prior” milestone events so deemed to be thereby achieved has not previously been paid, it shall thereupon
also be paid, forthwith (unless the deemed-achieved milestone event has already been achieved and paid for three times).

 

5.4         Royalty,
Etc. Payments for Licensed Products.

 

(a)       With respect to
Net Sales of all Licensed Products which are Covered under a Licensor Patent as of the time of the Net Sales: As further consideration
for Licensor’s grant of the rights and licenses to TGTX hereunder, TGTX shall pay to Licensor a royalty on aggregate annual
worldwide Net Sales of all such Licensed Products by TGTX and its Affiliates and Sublicensees (but excluding Net Sales of a given
Licensed Product after its applicable Royalty Term), at the percentage rates set forth below:

 

	Annual Worldwide Net Sales of All (Covered) Licensed

 Products per Calendar Year (US Dollars)	 	Incremental 
 Royalty Rate	 
	For Net Sales of such Licensed Products from $0 up to and including $1,000,000,000	 	 	6	%
	For that portion of Net Sales of such Licensed Products that is greater than $1,000,000,000	 	 	9.5	%

 

By way of illustration,
assume in a Calendar Year that aggregate worldwide annual Net Sales of all such Licensed Products total $1,950,000,000. The total
royalties due and payable by TGTX to Licensor for such Net Sales would be $150,250,000, calculated as follows:

 

$1,000,000,000 x 6%  =
$60,000,000

$950,000,000 x 9.5%  =
$90,250,000

Total Royalty  = $150,250,000

 

(b)       With respect to
Net Sales of all Licensed Products which are not Covered under any Licensor Patent as of the time of the Net Sales: In addition,
as further consideration for Licensor’s grant of the Licensed Know-How rights and licenses to TGTX hereunder, TGTX shall
pay to Licensor a payment in the nature of royalties on aggregate annual worldwide Net Sales of all such Licensed Products by TGTX
and its Affiliates and Sublicensees (but excluding Net Sales of a given Licensed Product after its applicable Royalty Term), at
the percentage rates set forth below:

 

    	 

    	 

    

 

	Annual Worldwide Net Sales of All (Uncovered) Licensed
 Products per Calendar Year (US Dollars)	 	Incremental 
 Royalty Rate	 
	For Net Sales of such Licensed Products from $0 up to and including $1,000,000,000	 	 	4.5	%
	For that portion of Net Sales of such Licensed Products that is greater than $1,000,000,000	 	 	7.125	%

 

Provided, that for the purposes of this
Section 5.4(b), only *% of the Net Sales of a Licensed Product in a country
during the time period when a Generic Supply of such Licensed Product is being lawfully Commercialized in such country, shall be
subject to such payment in the nature of royalties and the other *% shall be excluded. A “Generic Supply”
of a Licensed Product shall be deemed to be being Commercialized in a country if and only if the aggregate market share of all
generic versions of such Licensed Product in such country in the calendar year in question is at least *%.

 

(c)       In establishing
the royalty/payment in the nature of royalties structure hereunder, the Parties recognize, and TGTX acknowledges, the substantial
value of the various obligations being undertaken by Licensor under this Agreement, in addition to the grant of the license under
the Licensor Patents, to enable the rapid and effective market introduction of the Licensed Products. The Parties have agreed to
the payment structure set forth herein as a convenient and fair mechanism to compensate Licensor for these obligations.

 

(d)       For purposes of
determining whether the Section 5.4(a) or Section 5.4(b) royalty/payment in the nature of royalties threshold has been attained,
only Net Sales that are subject to a Section 5.4(a) payment or a Section 5.4(b) payment, respectively, shall be included in the
total amount of Net Sales and any Net Sales that are not subject to such a respective payment shall be excluded. In addition, in
no event shall the manufacture of a Licensed Product give rise to a royalty/payment in the nature of royalties obligation until
the particular unit of Licensed Product is sold; but if Net Sales of a particular unit of Licensed Product might or might not be
subject to a royalty/payment in the nature of royalties payment (e.g., manufactured in Country A where the Royalty Term has expired
but sold in Country B where the Royalty Term has not expired), the sale shall be deemed to be subject to a royalty/payment in the
nature of royalties payment. For clarity, TGTX’s obligation to pay royalties to Licensor under Section 5.4(a) is imposed
only once with respect to the same unit of Licensed Product regardless of the number of Licensor Patents pertaining thereto or
the number of times such Licensed Product has been sold or transferred to a Person.

 

(e)       On a Licensed
Product by Licensed Product and country-by-country basis, upon expiration of the Royalty Term for a Licensed Product in a country,
the rights, licenses and sublicenses granted to TGTX hereunder with respect to such Licensed Product in such country shall continue
in effect but become fully paid-up, royalty-free, transferable (to the extent not transferable previously), perpetual and irrevocable.

 

5.5       Timing of
Payment. Royalties/payments in the nature of royalties payable under Section 5.4 shall be payable on actual Net Sales and shall
accrue at the time provided therefor by US GAAP. Royalty/payment in the nature of royalties obligations that have accrued during
a particular Calendar Quarter shall be paid, on a Calendar Quarter basis, within 30 days after the end of each Calendar Quarter
during which the royalty/payment in the nature of royalties obligation accrued; provided that within 50 days after the conclusion
of each Calendar Year TGTX shall provide notice to Licensor of any adjustments necessary to account for any royalties/payment in
the nature of royalties which were overpaid or underpaid for such prior Calendar Year’s Calendar Quarters, and the Parties
shall promptly true-up based on such adjustments, provided however, the lapse of such 50-day period shall not impact the right
of TGTX to credit any over-payments discovered during an audit against future royalties due under Section 5.7 hereof.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	 

    	 

    

 

5.6         Royalty (Etc.)
Reports and Records Retention. Within 60 days after the end of each Calendar Quarter during which Licensed Products have been
sold, TGTX shall deliver to Licensor, together with the applicable royalty/payment in the nature of royalties payment due, a written
report, on a Licensed Product-by-Licensed Product (and specifying non-Covered status, as applicable) and country-by-country basis,
of (a) gross invoiced (or otherwise charged) amounts of sales, by TGTX and its Affiliates and Sublicensees, of Licensed Products
subject to royalty payments for such Calendar Quarter (and, if non-Covered, subject to royalty/payment in the nature of royalties
payments for such Calendar Quarter), (b) amounts deducted by category (following the definition of Net Sales) from such gross invoiced
amounts to calculate Net Sales, (c) Net Sales subject to royalty or royalty/payment in the nature of royalties payments for such
Calendar Quarter and Calendar Year to date and (d) the corresponding royalty or royalty/payment in the nature of royalties. Such
report shall be deemed “Confidential Information” of TGTX subject to the obligations of Article VII of this Agreement.
For three years after each sale of a Licensed Product (whether Covered or not), TGTX shall keep (and shall ensure that its Affiliates
and Sublicensees shall keep) complete and accurate records of such sale in sufficient detail to confirm the accuracy of the royalty
or royalty/payment in the nature of royalties calculations hereunder.

 

5.7         Audits.

 

(a)       From the First
Commercial Sale (of the first Licensed Product to have a First Commercial Sale) until one Calendar Year after the conclusion of
the final Royalty Term, upon the written request of Licensor, and not more than once in each Calendar Year, TGTX shall permit,
shall cause its Affiliates and Sublicensees to permit, an independent certified public accounting firm of nationally recognized
standing selected by Licensor (who has not been engaged by Licensor to provide services in any other capacity at any time during
the three-year period before such selection), and reasonably acceptable to TGTX or such Affiliate or Sublicensee, to have access
to and to review, during normal business hours upon reasonable prior written notice, the applicable records of TGTX and its Affiliates
or Sublicensees to verify the accuracy of the royalty and payment in the nature of royalties reports and payments under this Article
V. Such review may cover: (i) the records for sales made in any Calendar Year ending not more than three years before the date
of such request, and (ii) only those periods that have not been subject to a prior audit.

 

(b)       If such accounting
firm concludes that additional royalties and/or royalties/payment in the nature of royalties were owed during such period, TGTX
shall pay the additional royalties and/or royalties/payment in the nature of royalties within 15 days after the date such public
accounting firm delivers to TGTX such accounting firm’s written report. If such accounting firm concludes that an overpayment
was made, such overpayment shall be fully creditable against amounts payable in subsequent payment periods or at TGTX’s request,
shall be reimbursed to TGTX within 30 days after the date such public accounting firm delivers such report to TGTX. If TGTX disagrees
with such calculation, TGTX may contest such calculation in writing – at which point the parties will work in good faith
to submit the matter to a mediator for resolution. If the parties are unable to reach an agreement via mediation, then TGTX may
initiate a court action to seek to recover the additional payment or to increase the amount of credit or reimbursement. Licensor
shall pay for the cost of any audit by Licensor, unless TGTX has underpaid Licensor by 5% or more for a specific royalty period,
in which case TGTX shall pay for the reasonable costs of audit.

 

    	 

    	 

    

  

(c)       Each Party shall
treat all information that it receives under this Section 5.7 in accordance with the confidentiality provisions of Article VII
of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with the audited Party
obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement, except
to the extent necessary for a Party to enforce its rights under the Agreement.

 

5.8         Mode of Payment
and Currency. All payments to Licensor under this Agreement, whether or not in respect of Net Sales or milestone events, shall
be made by deposit of US Dollars in the requisite amount to such bank account as Licensor may from time to time designate by advance
written notice to TGTX. Conversion of sales or expenses recorded in local
currencies to Dollars will be performed in a manner consistent with TGTX’s normal practices used to prepare its audited financial
statements for external reporting purposes, provided that such practices use a widely accepted source of published exchange rates.
Based on the resulting Net Sales in US Dollars, the then applicable royalties/payment in the nature of royalties shall be
calculated.

 

5.9         Late Payments.
If a Party does not receive payment of any sum due to it on or before
the due date therefor, simple interest shall thereafter accrue on the sum due to such Party from the due date until the date of
payment at a rate equal to the lesser of (a) US dollar one-month LIBOR  plus 500 basis points, or (b) the maximum rate permissible
under applicable Law. Accrual and payment of interest shall not be deemed to excuse or cure breaches of contract arising from late
payment or nonpayment.

 

5.10       Taxes.
All amounts due hereunder exclude all applicable sales, use, and other taxes and duties, and TGTX shall be responsible for payment
of all such taxes (other than taxes based on Licensor’s income) and duties and any related penalties and interest, arising
from the payment of amounts due under this Agreement. The Parties agree to cooperate with one another and use Commercially Reasonable
Efforts to avoid or reduce tax withholding or similar obligations in respect of royalties, payments in the nature of royalties,
milestone payments, and other payments made by TGTX to Licensor under this Agreement. To the extent TGTX is required to withhold
taxes on any payment to Licensor, TGTX shall pay the amounts of such taxes to the proper governmental authority in a timely manner
and promptly transmit to Licensor official receipts issued by the appropriate taxing authority and/or an official tax certificate,
or such other evidence as Licensor may reasonably request, to establish that such taxes have been paid. Licensor shall provide
TGTX any tax forms that may be reasonably necessary in order for TGTX to not withhold tax or to withhold tax at a reduced rate
under an applicable bilateral income tax treaty. Licensor shall use Commercially Reasonable Efforts to provide any such tax forms
to TGTX at least 45 days before the due date for any payment for which Licensor desires that TGTX apply a reduced withholding rate.
Each Party shall provide the others with reasonable assistance to enable the recovery, as permitted by applicable law, of withholding
taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the
benefit of the Party bearing such withholding tax or value added tax. Licensor shall indemnify and hold TGTX harmless from and
against any penalties, interest or other tax liability arising from any failure by TGTX (at the express request of Licensor) to
withhold or by reduction (at the express request of Licensor) in its withholding.

 

    	 

    	 

    

  

ARTICLE VI

Inventions and Patents

 

6.1        Third Party
Inventions and Know-How. As between Licensor and TGTX, all inventions and Know-How made by a Third Party in the course of the
Development Program shall be owned by TGTX.

 

6.2        Patent Prosecution
and Maintenance.

 

(a)       Licensor Patents.
Licensor shall have the first right to file, prosecute and maintain Licensor Patents in Licensor’s name.

 

(b)       New or Revised
Applications. Licensor will, upon forming an intention to file or revise one or more patent applications which would become
or are Licensor Patent Rights subject to the License grant in Article II, promptly inform TGTX of such intention, and will provide
TGTX with the opportunity to comment on the content of such Licensor patent application before so filing or revising. Licensor
shall consider any such reasonable TGTX comments in good faith.

 

(c)       Liaising. Licensor
shall keep TGTX promptly and regularly informed of the course of the filing and prosecution of Licensor Patents or related proceedings
(e.g. interferences, oppositions, reexaminations, reissues, revocations or nullifications) in a timely manner, and to take into
consideration the advice and recommendations of TGTX.

 

(d)       Election Not
to File/Prosecute/Maintain Licensor Patents. TGTX acknowledges and agrees that Licensor shall not be required to file, prosecute
or maintain Patent Rights for the Licensor Patents, provided, however, if Licensor decides to not pursue or maintain any such Patent
Rights then Licensor shall provide TGTX with at least 30 days’ notice before discontinuing the filing, prosecution or maintenance
of such Patent Rights so that TGTX may assume responsibility for such activities in Licensor’s name but at TGTX’s expense.
In such event, TGTX will no longer owe any royalty obligation on account of such (country-level) Patent Rights assumed by TGTX.

 

6.3        Certification
under Drug Price Competition and Patent Restoration Act. Each of Licensor and TGTX shall immediately give written notice to
the other of any certification of which they become aware filed pursuant to 21 U.S.C. Section 355(b)(2)(A) (or any amendment or
successor statute thereto) claiming that any Licensor Patents covering a Compound or a Licensed Product, or the manufacture or
use of each of the foregoing, are invalid or unenforceable, or that infringement will not arise from the manufacture, use or sale
in the US of a Licensed Product by a Third Party.

 

6.4        Listing of
Patents. TGTX shall have the sole right to determine which of the Licensor Patents, if any, shall be listed for inclusion in
the Approved Drug Products with Therapeutic Equivalence Evaluations publication pursuant to 21 U.S.C. Section 355, or any successor
Law in the United States, together with any comparable Laws in any other country. Licensor will co-operate with TGTX to list any
of said Licensor Patents.

 

6.5        Enforcement
of Patents.

 

(a)       Notice.
If either Licensor or TGTX believes that a Licensor Patent is being infringed in the Field, or that Licensor Know-How has been
misappropriated in the Field, by a Third Party or if a Third Party claims that any Licensor Patent is invalid or unenforceable,
the Party possessing such knowledge or belief shall notify the other and provide it with details of such infringement, misappropriation
or claim that are known by such Party.

 

    	 

    	 

    

  

(b)       Right to Bring
an Action for Licensor’s Patents. If such infringement, misappropriation or claim is in one or more of the Major Markets
in respect of Licensor Patents, Licensor shall have the right to attempt to resolve such infringement, misappropriation or claim,
including by filing an infringement suit, defending against or bringing a declaratory judgment action as to such claim or taking
other similar action (each, “initiation” of an “Action”) and (subject to Section 6.5(e)) to compromise
or settle such infringement or claim. TGTX may, in its sole discretion and at its expense, join in any such Action and in such
case shall reasonably cooperate with Licensor. If Licensor does not intend to initiate an Action, Licensor shall promptly inform
TGTX. If Licensor does not initiate an Action with respect to such an infringement or claim within 180 days following notice thereof,
TGTX shall have the right to attempt to resolve such infringement, misappropriation or claim, including by initiating an Action,
and (subject to Section 6.5(e)) to compromise or settle such infringement, misappropriation or claim. At TGTX’s request,
Licensor shall immediately provide TGTX with all relevant documentation (as may be requested by TGTX) evidencing that TGTX is validly
empowered by the Licensor to initiate an Action. Licensor shall be under the obligation to join TGTX in its Action if TGTX determines
that this is necessary to demonstrate “standing to sue.” The Party initiating such Action shall have the sole and exclusive
right to select counsel for any suit initiated by it pursuant to this Section 6.5. If a Party initiates an Action but then elects
not to pursue the Action, the other Party shall have the right (but not the obligation) to take over the Action, in which case
the second Party shall be deemed to have been the initiating Party.

 

(c)       Costs of an
Action. Subject to the respective indemnity obligations of the Parties set forth in Article IX and subject to Section 6.5(f),
each Party involved in an Action under Section 6.5(b) shall pay its own costs and expenses incurred in connection with such Action.

 

(d)       Settlement.
No Party shall settle or otherwise compromise (or resolve by consent to the entry of judgment upon) any Action by admitting that
any Licensor Patent is to any extent invalid or unenforceable, or that any Licensor Know-How is not protected or has not been misappropriated,
without the other Party’s prior written consent, and, in the case of Licensor, Licensor may not settle or otherwise compromise
(or resolve by consent to the entry of judgment upon) an Action in a way that adversely affects or would be reasonably expected
to adversely affect any of TGTX’s rights or benefits hereunder with respect to any Licensor Technology or any Licensed Product,
without TGTX’s prior written consent.

 

(e)       Reasonable
Assistance. Each Party (if it is not the Party enforcing or defending Licensor’s Patent Rights) shall provide reasonable
assistance to the other Party, including providing access to relevant documents and other evidence and making its employees and
consultants available, subject to the other Party’s reimbursement of any reasonable out-of-pocket expenses incurred on an
on-going basis by the non-enforcing or non-defending Party in providing such assistance.

 

(f)       Distribution
of Amounts Recovered. Any amounts recovered by the Party initiating an Action pursuant to this Section 6.5, whether by settlement
or judgment, shall be allocated in the following order: (i) to reimburse the Party initiating such Action for any costs incurred;
(ii) to reimburse the Party not initiating such Action for its costs incurred in such Action, if it joins (as opposed to taking
over) such Action; and (iii) the remaining amount of such recovery shall (A) if TGTX initiated the Action, the remainder shall
be allocated to TGTX and the portion thereof attributable to “lost sales” shall be deemed to be Net Sales for the Calendar
Quarter in which the amount is actually received by TGTX and TGTX shall pay to Licensor a royalty on such portion based on the
royalty rates set forth in Section 5.4(a), and the portion thereof not attributable to “lost sales” shall be allocated
to TGTX and (B) if Licensor initiated the Action, the remainder shall be allocated to TGTX and the portion thereof attributable
to “lost sales” shall be deemed to be Net Sales for the Calendar Quarter in which the amount is actually received by
TGTX and TGTX shall pay to Licensor a royalty on such portion based on the royalty rates set forth in Section 5.4(a), and the portion
thereof not attributable to “lost sales” shall be allocated to 50% to Licensor and 50% to TGTX.

 

    	 

    	 

    

 

6.6           Third
Party Actions Claiming Infringement.

 

(a)          Notice.
If either Licensor or TGTX becomes aware of any Third Party Action, such Party shall promptly notify the other of all details regarding
such claim or action that is reasonably available to such Party.

 

(b)          Right
to Defend. TGTX shall have the right, at its sole expense, but not the obligation, to defend a Third Party Action described
in Section 6.6(a) and (subject to Section 6.6(f)) to compromise or settle such Third Party Action. If TGTX declines or fails to
assert its intention to defend such Third Party Action within 40 days of receipt/sending of notice under Section 6.6(a), then Licensor
shall have the right, at its sole expense, to defend such Third Party Action and (subject to Section 6.6(f)) to compromise or settle
such Third Party Action. The Party defending such Third Party Action shall have the sole and exclusive right to select counsel
for such Third Party Action.

 

(c)          Consultation.
The Party defending a Third Party Action pursuant to Section 6.6(b) shall be the “Controlling Party”. The Controlling
Party shall consult with the non-Controlling Party, pursuant to an appropriate joint defense or common interest agreement, on all
material aspects of the defense. The non-Controlling Party shall have a reasonable opportunity for meaningful participation in
decision-making and formulation of defense strategy. The Parties shall reasonably cooperate with each other in all such actions
or proceedings. The non-Controlling Party will be entitled to join the Third Party Action and be represented by independent counsel
of its own choice at its own expense.

 

(d)          Appeal.
In the event that a judgment in a Third Party Action is entered against either Party and an appeal is available, the Controlling
Party shall have the first right, but not the obligation, to file such appeal. In the event the Controlling Party does not desire
to file such an appeal, it will promptly, in a reasonable time period (i.e., with sufficient time for the non-Controlling Party
to take whatever action may be necessary) before the date on which such right to appeal will lapse or otherwise diminish, permit
the non-Controlling Party to pursue such appeal at such non-Controlling Party’s own cost and expense. If applicable Law requires
the other Party’s involvement in an appeal, the other Party shall be a nominal party in the appeal and shall provide reasonable
cooperation to such Party at such Party’s expense.

 

(e)          Costs
of an Action. Subject to the respective indemnity obligations of the Parties set forth in Article IX, the Controlling Party
shall pay all costs and expenses associated with such Third Party Action other than the expenses of the other Party if the other
Party elects to join such Third Party Action (as provided in the last sentence of Section 6.6(c)).

 

    	 

    	 

    

  

(f)          No
Settlement without Consent. Neither Licensor or TGTX shall settle or otherwise compromise (or resolve by consent to the entry
of judgment upon) any Third Party Action by admitting that any Licensor Patent is to any extent invalid or unenforceable or that
any Licensed Product, or its use, Development, importation, manufacture or sale infringes such Third Party’s intellectual
property rights, in each case without the other Party’s prior written consent, and, in the case of Licensor, Licensor may
not settle or otherwise compromise (or resolve by consent to the entry of judgment upon) a Third Party Action in a way that adversely
affects or would be reasonably expected to adversely affect TGTX’s rights and benefits hereunder with respect to any Licensor
Technology or any Licensed Product, without TGTX’s prior written consent.

 

ARTICLE VII

CONFIDENTIALITY

 

7.1           Definitions.
The Parties recognize that disclosures of Confidential Information between them before the Effective Date were subject to the Confidential
Disclosure Agreement between them dated April 29, 2014. TGTX and Licensor each recognizes that during the Term, it may be necessary
for a Party (the “Disclosing Party”) to provide Confidential Information (as defined herein) to another Party
(the “Receiving Party”) that is highly valuable, the disclosure of which would be highly prejudicial to such
Party. The disclosure and use of Confidential Information shall be governed by the provisions of this Article VII. Neither TGTX
nor Licensor shall use the other’s Confidential Information except as expressly permitted in this Agreement. For purposes
of this Agreement, “Confidential Information” means all information (including information relating to the business,
operations and products of a Party or any of its Affiliates) disclosed by the Disclosing Party to the Receiving Party and which
reasonably ought to have been understood to be confidential and/or non-public information at the time disclosed to the Receiving
Party, or which is designated in writing by the Disclosing Party as “Confidential” (or equivalent), or which when disclosed
orally to the Receiving Party is declared to be confidential by the Disclosing Party and is so confirmed in a writing delivered
to the Receiving Party within 30 days after such oral disclosure, including but not limited to any technical information, Know-How,
trade secrets, or inventions (whether patentable or not), that such Party discloses to another Party under this Agreement, or otherwise
becomes known to another Party by virtue of or that relates to this Agreement.

 

7.2           Obligation.
Licensor and TGTX agree that they will disclose the other Party’s Confidential Information to its own (or its respective
Affiliate’s, or with respect to TGTX, its Sublicensees’) officers, employees, consultants and agents only if and to
the extent necessary to carry out their respective responsibilities under this Agreement or in accordance with the exercise of
their rights under this Agreement, and such disclosure shall be limited to the maximum extent possible consistent with such responsibilities
and rights. Except as set forth in the foregoing sentence, no Party shall disclose Confidential Information of the other to any
Third Party without the other’s prior written consent. In all events, however, any and all disclosure to a Third Party (or
to any such Affiliate or Sublicensee) shall be pursuant to the terms of a non-disclosure/nonuse agreement no less restrictive than
this Article VII. The Party which disclosed Confidential Information of the other to any Third Party (or to any such Affiliate
or Sublicensee) shall be responsible and liable for any disclosure or use by such Third Party, Affiliate or Sublicensee (or its
disclosees) which would have violated this Agreement if committed by the Party itself. No Party shall use Confidential Information
of the other except as expressly allowed by and for the purposes of this Agreement. Each Party shall take such action to preserve
the confidentiality of each other’s Confidential Information as it would customarily take to preserve the confidentiality
of its own Confidential Information (but in no event less than a reasonable standard of care). Upon expiration or termination of
this Agreement, each Party, upon the other’s request, shall return or destroy (at Disclosing Party’s discretion) all
the Confidential Information disclosed to the other Party pursuant to this Agreement, including all copies and extracts of documents,
within 60 days after the request, except for one archival copy (and such electronic copies that exist as part of the Party’s
computer systems, network storage systems and electronic backup systems) of such materials solely to be able to monitor its obligations
that survive under this Agreement.

 

    	 

    	 

    

  

7.3           Exceptions.
The non-use and non-disclosure obligations set forth in this Article VII shall not apply to any Confidential Information, or portion
thereof, that the Receiving Party can demonstrate by competent evidence:

 

(a)          at
the time of disclosure is in the public domain;

 

(b)          after
disclosure, becomes part of the public domain, by publication or otherwise, through no fault of the Receiving Party or its disclosees;

 

(c)          is
made available to the Receiving Party by an independent Third Party without obligation of confidentiality; provided, however, that
to the Receiving Party’s knowledge, such information was not obtained by said Third Party, directly or indirectly, from the
Disclosing Party hereunder; or

 

(d)          is
independently developed by an employee of the Receiving Party not accessing or utilizing the Disclosing Party’s information.

 

In addition, the Receiving Party may disclose
information that is required to be disclosed by law, by a valid order of a court or by order or regulation of a governmental agency
including but not limited to, regulations of the SEC or in the course of arbitration or litigation; provided, however, that in
all cases the Receiving Party shall give the other party prompt notice of the pending disclosure and make a reasonable effort to
obtain, or to assist the Disclosing Party in obtaining, a protective order or confidential-treatment order preventing or limiting
(to the greatest possible extent and for the longest possible period) the disclosure and/or requiring that the Confidential Information
so disclosed be used only for the purposes for which the law or regulation required, or for which the order was issued.

 

7.4           Third
Party Information. The Parties acknowledge that the defined term “Confidential Information” shall include not only
a Disclosing Party’s own Confidential Information but also Confidential Information of a Third Party which is in the possession
of a Disclosing Party. TGTX and Licensor agree not to disclose to the other any Confidential Information of a Third Party which
is in the possession of such Party, unless the other has given an express prior written consent (which specifies the owner of such
Confidential Information) to receive such particular Confidential Information.

 

7.5           Press
Releases and Disclosure. Either Party may make press releases or public announcements regarding this Agreement or any matter
covered by this Agreement, including the Development or Commercialization of Licensed Products, but such Party shall use Commercially
Reasonable Efforts to provide the text of such planned disclosure to the other Party sufficiently in advance of the scheduled disclosure
to afford such other Party a reasonable opportunity to review and comment upon the proposed text and the timing of such disclosure,
and shall consider all reasonable comments of the other Party regarding such disclosure. (Provided, that no Party shall use the
trademark or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release
or public disclosure relating to this Agreement or its subject matter, except as may be required by Law or required by the rules
of an applicable US national securities exchange or except with the prior express written permission of such other Party, such
permission not to be unreasonably withheld.) Notwithstanding the above, once a public disclosure has been made, either Party shall
be free to disclose to third parties any information contained in said public disclosure, without further pre-review.

 

    	 

    	 

    

  

7.6           Publication
Rights. Until the first anniversary of the Effective Date, the following restrictions shall apply with respect to possible
disclosure by either Party of the other Party’s Confidential Information relating to Licensed Products in any publication
or presentation. A Party (the “Publishing Party”) shall provide the other Party with a copy of any proposed
publication or presentation at least 30 days before submission for publication by the Publishing Party or its Affiliates so as
to provide such other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain
the Confidential Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement.
The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies (“Notice”)
the Publishing Party in writing, within 30 days after receipt of the copy of the proposed publication or presentation, that such
publication or presentation in its reasonable judgment (a) contains an invention, solely or jointly conceived or reduced to practice
by the other Party, for which the other Party reasonably desires to obtain patent protection or (b) could be expected to have a
material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing
Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. In
the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent
application(s) on such invention, and in no event less than 90 days after the date of the Notice. In the case of Confidential Information,
any of the non-publishing Party’s Confidential Information shall be deleted as requested. The Parties hereby agree that the
need for such publication review may diminish over time and agree, every six months, to discuss and attempt to agree upon whether
and/or when the obligations under this Section 7.6 may be discontinued.

 

ARTICLE VIII

REPRESENTATIONS, WARRANTIES AND COVENANTS

 

8.1           Representations
and Warranties. (a) TGTX represents and warrants to Licensor, and (b) Licensor represents and warrants to TGTX, in each case
as of the Effective Date:

 

(a)          Such
Party is a corporation duly organized and validly existing under the Laws of the jurisdiction of its incorporation;

 

(b)          Such
Party has all right, power and authority to enter into this Agreement, and to perform its obligations under this Agreement;

 

(c)          Such
Party has taken all action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations
under this Agreement;

 

(d)          This
Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance
with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency,
reorganization, moratorium and other Laws relating to or affecting creditors’ rights generally and by general equitable principles;

 

    	 

    	 

    

  

(e)          To
the best of such party’s knowledge, the execution, delivery and performance of this Agreement by such Party does not and
will not conflict with, breach or create in any Third Party the right to accelerate, terminate or modify any agreement or instrument
to which such Party is a party or by which such Party is bound;

 

(f)          To
the best of such party’s knowledge, all consents, approvals and authorizations from all governmental authorities or other
Third Parties required to be obtained by such Party in connection with the execution and delivery of this Agreement have been obtained;
and the execution, delivery and performance of this Agreement by such Party does not and will not violate any Law of any Governmental
Body having authority over such Party;

 

(g)          No
person or entity has or will have, as a result of the execution and delivery of or as a result of the transactions contemplated
by this Agreement, any right, interest or valid claim against or upon such Party for any commission, fee or other compensation
as a finder or broker because of any act by such Party or its Affiliates, agents or Sublicensees; and

 

(h)          To
the best of such party’s knowledge, no agreement between it and any Third Party is in conflict with the rights granted to
any other party pursuant to this Agreement.

 

8.2          Additional
Representations and Warranties of Licensor. Licensor represents and warrants to TGTX that:

 

(a)          No
consent by any Third Party or Governmental Body is required with respect to the execution and delivery of this Agreement by Licensor
or the consummation by Licensor of the transactions contemplated hereby;

 

(b)          No
claims have been asserted or threatened by any Person (i) challenging the validity, effective status, or ownership of Licensor
Technology, and/or (ii) to the effect that the use, reproduction, modification, manufacturing, distribution, licensing, sublicensing,
sale or any other exercise of rights in any of Licensor Technology infringes or will infringe on any intellectual property right
of any Person; and no such claims have been asserted or are threatened;

 

(c)          The
Licensor Patents are subsisting and are not the subject of any litigation procedure, discovery process, interference, reissue,
reexamination, opposition, appeal proceedings or any other legal dispute;

 

(d)          The
Licensor Patents constitute all Patent Rights owned or Controlled by Licensor that pertain directly and particularly to the research,
Development, manufacture, use and Commercialization of the Licensed Products as currently envisioned; and

 

(e)          No
Third Party has filed, pursued or maintained or threatened in writing to file, pursue or maintain any claim, lawsuit, charge, complaint
or other action alleging that any Licensor Technology is invalid or unenforceable.

 

    	 

    	 

    

  

8.3           Disclaimer.
Notwithstanding the representations and warranties set forth in this Article VIII, TGTX acknowledges and accepts the risks inherent
in attempting to Develop and Commercialize any pharmaceutical product. There is no implied representation that the Compounds can
be successfully Developed or Commercialized. The representations and warranties set forth in this Article VIII are provided in
lieu of, and EACH PARTY HEREBY DISCLAIMS, all other warranties, express and implied, relating to the subject matter of this
Agreement, the Licensor Technology, the Compounds and/or the Licensed Products, including but not limited to the implied warranties
of merchantability and fitness for a particular purpose, title and non-infringement of third party rights. Each Party’s
representations and warranties under this Agreement are solely for the benefit of the other Party and may be asserted only by the
other Party and not by any Affiliate, Sublicensee or any customer of the other Party, its Affiliates or Sublicensees. Each Party,
its Affiliates and Sublicensees shall be solely responsible for all representations and warranties that it, its Affiliates or Sublicensees
make to any customer, Affiliates or Sublicensees.

 

ARTICLE
IX

INDEMNIFICATION; LIMITATION OF LIABILITY; INSURANCE

 

9.1           Indemnification
by TGTX. TGTX shall indemnify, defend and hold Licensor and its Affiliates, and each of their respective employees, officers,
directors and agents (the “Licensor Indemnitees”) harmless from and against any and all actions, judgments,
settlements, liabilities, damages, penalties, fines, losses, costs and expenses (including reasonable attorneys’ fees and
expenses) to the extent arising out of any Third Party claim, demand, action or other proceeding (each, a “Claim”)
related to (a) TGTX’s performance of its obligations or exercise (by it or its Affiliates or Sublicensees) of its rights
under this Agreement; or (b) breach by TGTX of its representations and warranties set forth in Article VIII; provided, however,
that TGTX’s obligations pursuant to this Section 9.1 shall not apply (x) to the extent such claims or suits result from the
gross negligence or willful misconduct of any of the Licensor Indemnitees, or (y) with respect to claims or suits arising out of
breach by Licensor of this Agreement, including without limitation of its or their representations and warranties set forth in
Article VIII.

 

9.2           Indemnification
by Licensor. Licensor shall indemnify, defend and hold TGTX and its Affiliates and each of their respective agents, employees,
officers and directors (the “TGTX Indemnitees”) harmless from and against any and all actions, judgments, settlements,
liabilities, damages, penalties, fines, losses, costs and expenses (including reasonable attorneys’ fees and expenses) to
the extent arising out of any and all Claims related to (a) Licensor’s performance of its obligations or exercise (by it
or its Affiliates) of its or their rights under this Agreement; or (b) breach by Licensor of its representations and warranties
set forth in Article VIII; provided, however, that Licensor’s obligations pursuant to this Section 9.2 shall not apply (x)
to the extent that such claims or suits result from the gross negligence or willful misconduct of any of the TGTX Indemnitees or
(y) with respect to claims or suits arising out of a breach by TGTX of this Agreement, including without limitation its representations
and warranties set forth in Article VIII.

 

9.3           No
Consequential, Etc., Damages. EXCEPT FOR DAMAGES FOR WHICH A PARTY IS RESPONSIBLE PURSUANT TO ITS INDEMNIFICATION OBLIGATIONS
SET FORTH IN ARTICLE IX, EACH PARTY SPECIFICALLY DISCLAIMS ALL LIABILITY FOR AND SHALL IN NO EVENT BE LIABLE TO ANY OTHER PARTY
OR TO ANY OTHER PARTY’S AFFILIATES FOR ANY INCIDENTAL, SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES, EXPENSES, LOST PROFITS,
LOST SAVINGS, INTERRUPTIONS OF BUSINESS OR OTHER DAMAGES OF ANY KIND OR CHARACTER WHATSOEVER ARISING OUT OF OR RELATED TO THIS
AGREEMENT OR THE DEVELOPMENT PROGRAM OR THE LICENSED TECHNOLOGY OR RESULTING FROM THE MANUFACTURE, HANDLING, MARKETING, SALE, DISTRIBUTION
OR USE OF LICENSED PRODUCTS, REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF
SUCH PARTY WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

    	 

    	 

    

  

9.4           Procedure.

 

(a)          The
Party or other Person intending to claim indemnification under this Article IX (an “Indemnified Party”) shall promptly
notify the opposed Party (the “Indemnifying Party”) of any Claim in respect of which the Indemnified Party intends
to claim such indemnification (provided, that no delay or deficiency on the part of the Indemnified Party in so notifying the Indemnifying
Party will relieve the Indemnifying Party of any liability or obligation under this Agreement except to the extent the Indemnifying
Party has suffered actual prejudice directly caused by the delay or other deficiency), and the Indemnifying Party shall assume
the defense thereof (with counsel selected by the Indemnifying Party and reasonably satisfactory to the Indemnified Party) whether
or not such Claim is rightfully brought; provided, however, that an Indemnified Party shall have the right to retain its own counsel
and to participate in the defense thereof, with the fees and expenses to be paid by the Indemnified Party unless the Indemnifying
Party does not assume the defense or unless a representation of both the Indemnified Party and the Indemnifying Party by the same
counsel would be inappropriate due to the actual or potential differing interests between them, in which case the reasonable fees
and expenses of counsel retained by the Indemnified Party shall be paid by the Indemnifying Party. (Provided, that in no event
shall the Indemnifying Party be required to pay for more than one separate counsel no matter the number or circumstances of all
Indemnified Parties.)

 

(b)          If
the Indemnifying Party shall fail to timely assume the defense of and reasonably defend such Claim, the Indemnified Party shall
have the right to retain or assume control of such defense and the Indemnifying Party shall pay (as incurred and on demand) the
fees and expenses of counsel retained by the Indemnified Party.

 

(c)          The
Indemnifying Party shall not be liable for the indemnification of any Claim settled (or resolved by consent to the entry of judgment)
without the written consent of the Indemnifying Party. Also, if the Indemnifying Party shall control the defense of any such Claim,
the Indemnifying Party shall have the right to settle such Claim; provided, that the Indemnifying Party shall obtain the prior
written consent (which shall not be unreasonably withheld or delayed) of the Indemnified Party before entering into any settlement
of (or resolving by consent to the entry of judgment upon) such Claim unless (i) there is no finding or admission of any violation
of law or any violation of the rights of any person by an Indemnified Party, no requirement that the Indemnified Party admit negligence,
fault or culpability, and no adverse effect on any other claims that may be made by or against the Indemnified Party and (ii) the
sole relief provided is monetary damages that are paid in full by the Indemnifying Party and such settlement does not require the
Indemnified Party to take (or refrain from taking) any action.

 

(d)          The
Indemnified Party, and its employees and agents, shall cooperate fully with the Indemnifying Party and its legal representatives
in the investigations of any Claim.

 

(e)          Regardless
of who controls the defense, each Party hereto shall reasonably cooperate in the defense as may be requested.

 

9.5           Expenses.
As the Parties intend complete indemnification, all costs and expenses of enforcing any provision of this Article IX shall also
be reimbursed by the Indemnifying Party..

 

    	 

    	 

    

  

9.6           Limitation
of Liability. EACH PARTY SHALL HAVE NO REMEDY, AND EACH PARTY SHALL HAVE NO LIABILITY, OTHER THAN AS EXPRESSLY SET FORTH IN
THIS AGREEMENT. EXCEPT WITH RESPECT TO THE INDEMNIFICATION SPECIFICALLY PROVIDED IN ARTICLE IX OR CLAIMS FOR NON-PAYMENT, IN NO
EVENT SHALL A PARTY’S TOTAL AGGREGATE LIABILITY FOR ALL CLAIMS ARISING OUT OF OR RELATED TO THIS AGREEMENT EXCEED 50% OF
THE AMOUNT PAID BY TGTX TO LICENSOR UNDER THIS AGREEMENT IN THE CASE OF LICENSOR OR EXCEED ONE MILLION DOLLARS IN THE CASE OF TGTX.
NO ACTION, REGARDLESS OF FORM, ARISING OUT OF OR RELATED TO THIS AGREEMENT MAY BE BROUGHT BY EITHER PARTY MORE THAN TWO YEARS AFTER
SUCH PARTY HAS KNOWLEDGE OF THE OCCURRENCE THAT GAVE RISE TO THE CAUSE OF ACTION OR AFTER EXPIRATION OF THE APPLICABLE STATUTORY
LIMITATIONS PERIOD, WHICHEVER IS SOONER.

 

9.7           Insurance.
During the Term and for three years thereafter, TGTX shall obtain and maintain, at its own cost and expense, product liability
insurance (or TGTX’s parent company shall obtain and maintain coverage for TGTX under its own product liability insurance
policies) in amounts, that are reasonable and customary in the United States pharmaceutical and biotechnology industry for companies
engaged in comparable activities, with Licensor identified as an additional named insured. It is understood and agreed that this
insurance shall not be construed to limit TGTX’s liability with respect to its indemnification obligations hereunder. TGTX
shall upon request provide to Licensor upon request a certificate evidencing the insurance TGTX is required to obtain and keep
in force under this Section 9.7.

 

ARTICLE
X

TERM AND TERMINATION

 

10.1         Term
and Expiration. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided
in this Article X, shall continue in full force and effect, on a country-by-country and Licensed Product-by-Licensed Product basis
until the Royalty Term in such country with respect to such Licensed Product expires, at which time this Agreement shall expire
in its entirety with respect to such Licensed Product in such country. (The “Term” shall mean the period from
the Effective Date until the earlier of termination of this Agreement as provided in this Article X or expiration of this Agreement
upon the expiration of the last-to-expire Royalty Term.) The Parties confirm that subject to the foregoing sentence, this Agreement
shall not be terminated or invalidated by any future determination that any or all of the Licensor Patents have expired or been
invalidated.

 

10.2         Termination
upon Material Breach. If a Party breaches any of its material obligations under this Agreement, the Party not in default may
give to the breaching Party a written notice specifying the nature of the default, requiring it to cure such breach, and, if desired,
stating its intention to terminate this Agreement if such breach is not cured. If such breach is not capable of being cured, or
is capable of being cured but nonetheless has not within 45 days after the receipt of such notice been cured, then the Party not
in default shall (in addition to and not in lieu of all other available rights and remedies) be entitled to at its option either
(a) terminate this Agreement immediately by written notice to the other Party, or (b) continue this Agreement in full force and
effect and seek any legal or equitable remedies that the non-breaching Party may have. In case of a breach of an obligation to
pay money, which obligation to pay is not disputed in good faith, the cure period shall be 15 days instead of 45 days. The Parties
agree that any failure by TGTX to pay when due 100% of such portion of any amount of money owing from TGTX to Licensor as is not
disputed in good faith by TGTX (subject to the 15-day cure period) shall conclusively be deemed to constitute a “material”
breach. Notwithstanding the foregoing provisions, in the event of a good-faith dispute as to whether any alleged breach is in fact
a breach, termination under this Section 10.2 in respect of such alleged breach shall not take effect unless and until (y) such
dispute is resolved (by court or arbitration decision or otherwise) in favor of the Party alleging the breach or (z) the breaching
Party’s denial that the alleged breach is in fact a breach ceases to be in good faith.

 

    	 

    	 

    

  

10.3         Termination
for Bankruptcy. Licensor may terminate this Agreement immediately upon written notice to TGTX in the event that TGTX
has a petition in bankruptcy filed against it that is not dismissed within 60 days of such filing, files a petition in bankruptcy,
or makes an assignment for the benefit of creditors. If TGTX has before such filing or such assignment entered into a written Sublicense
which complies with Section 2.2, then the Sublicensee thereunder shall have the right to, by but only by delivering to Licensor
within 30 days after such termination a written election to do so and a written assumption of all of TGTX’s past and future
obligations, liabilities and duties under this Agreement, convert its Sublicense into a direct of license from Licensor of the
same technology, for the same field and for the same territory, as had been provided for in the Sublicense and otherwise on the
same terms and conditions as are set forth in this Agreement as if such Sublicensee were TGTX hereunder. TGTX may terminate this
Agreement immediately upon written notice to Licensor in the event that Licensor has a petition in bankruptcy filed against it
that is not dismissed within 60 days of such filing, files a petition in bankruptcy, or makes an assignment for the benefit of
creditors.

 

10.4         Effects
of Termination/Expiration.

 

(a)          Articles
I (Definitions), VII (Confidentiality), IX (Indemnification; Limitation of Liability; Insurance) and XI (Miscellaneous Provisions)
and Sections 5.6 (Royalty Reports and Records Retention), 5.7 (Audits), 5.9 (Late Payments), 5.10 (Taxes) and 10.4 (Effects
of Termination/Expiration) hereof shall survive the expiration or termination of this Agreement for any reason. In addition, upon
termination of this Agreement by TGTX pursuant to Sections 10.2 or 10.3, then Section 6.6 (Third Party Actions Claiming Infringement)
shall survive the expiration or termination of this Agreement.

 

(b)          Termination
or expiration of this Agreement shall not relieve the Parties of any liability that accrued hereunder before the effective date
of such termination or expiration. In addition, termination or expiration of this Agreement shall not preclude either Party from
pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this Agreement nor
prejudice either Party’s right to obtain performance of any obligation.

 

(c)          Upon
termination of this Agreement by Licensor pursuant to Section 10.2, all licenses granted to TGTX hereunder shall terminate. If
TGTX has before the breach entered into a written Sublicense which complies with Section 2.2, then the Sublicensee thereunder shall
have the right to, by but only by delivering to Licensor within 30 days after such termination a written election to do so and
a written assumption of all of TGTX’s past and future obligations, liabilities and duties under this Agreement and a tender
of funds or other action to directly and fully cure TGTX’s breach, convert its Sublicense into a direct of license from Licensor
of the same technology, for the same field and for the same territory, as had been provided for in the Sublicense and otherwise
on the same terms and conditions as are set forth in this Agreement as if such Sublicensee were TGTX hereunder. In the event of
termination by TGTX pursuant to Section 10.2, the licenses granted to TGTX hereunder shall continue in effect but become fully
paid-up, royalty-free, transferable (to the extent not transferable previously), perpetual and irrevocable.

 

    	 

    	 

    

  

ARTICLE
XI

MISCELLANEOUS PROVISIONS

 

11.1       Relationship
of the Parties. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, joint venture
or employer-employee relationship between the Parties. No Party shall have any right or authority to commit or legally bind any
other Party in any way whatsoever including, without limitation, the making of any agreement, representation or warranty and each
Party agrees to not purport to do so.

 

11.2       Assignment.

 

(a)          Any
assignment not in accordance with this Section 11.2 shall be void.

 

(b)          No
assignment shall relieve the assigning Party of any of its responsibilities or obligations hereunder.

 

(c)          TGTX
may not transfer or assign its rights or licenses or delegate its obligations under this Agreement, in whole or in part, by operation
of law or otherwise, to any Third Party without the prior written consent of Licensor, which consent shall not be unreasonably
withheld, conditioned or delayed; provided that, notwithstanding the foregoing, TGTX may assign its rights or licenses and/or
delegate its obligations under this Agreement to an Affiliate or to a successor to all or substantially all of TGTX’s assets,
whether by way of merger, sale of all or substantially all of its assets, sale of stock or otherwise, without Licensor’s
prior written consent. As a condition to any permitted assignment hereunder, the assignee must expressly assume, in a writing delivered
to Licensor (and in a form reasonably acceptable to Licensor) all of TGTX’s obligations under this Agreement, whether arising
before, at or after the assignment.

 

(d)          Licensor
may not transfer or assign its rights or delegate its obligations under this Agreement, in whole or in part, by operation of law
or otherwise, to any Third Party without the prior written consent of TGTX, which consent shall not be unreasonably withheld, conditioned
or delayed; provided that, notwithstanding the foregoing, Licensor may, without TGTX’s prior written consent, assign
its rights and/or delegate its obligations under this Agreement to an Affiliate, or to any person in a transaction in which Licensor
also assigns all of its right, title and interest in all or substantially all of its Licensor Technology assets, including without
limitation, intellectual property rights, to the same party contemporaneous with the assignment of this Agreement, or to a successor,
whether by way of merger, sale of all or substantially all of its assets, sale of stock or otherwise. As a condition to any permitted
assignment hereunder, the assignee must expressly assume, in a writing delivered to TGTX (and in a form reasonably acceptable to
TGTX) all of Licensor’s obligations under this Agreement, whether arising before, at or after the assignment.

 

11.3         Further
Actions. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may
be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

    	 

    	 

    

  

11.4         Force
Majeure. No Party shall be liable to any other Party or be deemed to have breached or defaulted under this Agreement for failure
or delay in the performance of any of its obligations under this Agreement (other than obligations for the payment of money) for
the time and to the extent such failure or delay is caused by or results from acts of God, earthquake, riot, civil commotion, terrorism,
war, strikes or other labor disputes, fire, flood, failure or delay of transportation, omissions or delays in acting by a governmental
authority, acts of a government or an agency thereof or judicial orders or decrees or restrictions or any other like reason which
is beyond the control of the respective Party. The Party affected by force majeure shall provide the other Party with full particulars
thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference
with its activities), and shall use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume
performance of its obligations hereunder as soon as practicable, and the time for performance shall be extended for a number of
days equal to the duration of the force majeure.

 

11.5         Entire
Agreement of the Parties; Amendments. This Agreement and the Schedules hereto constitute and contain the entire understanding
and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior or contemporaneous
negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject
matter (provided, that any and all previous nondisclosure/nonuse obligations are not superseded and remain in full force and effect
in addition to the nondisclosure/nonuse provisions hereof). Each Party acknowledges that it has not relied, in deciding whether
to enter into this Agreement on this Agreement’s expressly stated terms and conditions, on any representations, warranties,
agreements, commitments or promises which are not expressly set forth within this Agreement. No modification or amendment of any
provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly
authorized officer of each Party.

 

11.6         Governing
Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York, excluding application
of any conflict of laws principles.

 

11.7         Notices
and Deliveries. Any notice, request, approval or consent required or permitted to be given under this Agreement shall be in
writing and shall be deemed to have been sufficiently given if and only if delivered in person, by email or by express courier
service to the Party to which it is directed at its physical or email address shown below or such other physical or email address
as such Party shall have last given by such written notice to the other Party.

 

If to TGTX, addressed to:

 

TG Therapeutics, Inc.

3 Columbus Circle, 15th Floor

New York, NY 10019

Attention: Michael S. Weiss, Executive Chairman, Interim
President and Chief Executive Officer

Email: msw@opuspointpartners.com

 

If to Licensor, addressed to:

 

General Counsel

Ligand Pharmaceuticals
Incorporated

11119 North
Torrey Pines Road, Suite 200

La Jolla,
CA 92037

Email: cberkman@ligand.com

 

    	 

    	 

    

  

11.8         Waiver.
No waiver of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and
signed by a duly authorized officer of the waiving Party. A waiver by a Party of any of the terms and conditions of this Agreement
in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term
or condition hereof.

 

11.9         Rights
and Remedies are Cumulative. Except to the extent expressly set forth herein, all rights, remedies, undertakings, obligations
and agreements contained in or available upon violation of this Agreement shall be cumulative and none of them shall be in limitation
of any other remedy or right authorized in law or in equity, or any undertaking, obligation or agreement of the applicable Party.

 

11.10         Severability.
This Agreement is severable. When possible, each provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable Law, but if any provision of this Agreement is held to be to any extent prohibited by or invalid under
applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement (or of such provision). The Parties shall make a good faith effort to replace the invalid or unenforceable
provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.

 

11.11         Third
Party Beneficiaries. Except for the rights of Indemnified Parties pursuant to Article IX hereof and the rights of Sublicensees
set forth in Sections 10.2 and 10.4(c), the terms and provisions of this Agreement are intended solely for the benefit of each
Party hereto and their respective successors or permitted assigns and it is not the intention of the Parties to confer third-party
beneficiary rights upon any other person, including without limitation Sublicensees. The enforcement of any obligation of Licensor
under this Agreement shall only be pursued by TGTX or such Indemnified Party, and not Sublicensees (except as set forth in Sections
10.2 and 10.4(c)).

 

11.12         No
Implied License. No right or license is granted to TGTX hereunder by implication, estoppel, or otherwise to any know-how, patent
or other intellectual property right owned or controlled by Licensor or its Affiliates, except by an express license granted hereunder.
No right or license is granted to Licensor hereunder by implication, estoppel, or otherwise to any know-how, patent or other intellectual
property right owned or controlled by TGTX or its Affiliates, except by an express license granted hereunder.

 

11.13         No
Right of Set-Off. Except as expressly provided in Section 5.7(b) of this Agreement, TGTX shall not have a right to set-off
any royalties, milestones or other amount due to Licensor under this Agreement against any damages incurred by TGTX for a breach
by Licensor of this Agreement.

 

11.14         Equitable
Relief. Each Party recognizes that the covenants and agreements herein and their continued performance as set forth in this
Agreement are necessary and critical to protect the legitimate interests of the other Party, that the other Party would not have
entered into this Agreement in the absence of such covenants and agreements and the assurance of continued performance as set forth
in this Agreement, and that a Party’s breach or threatened breach of such covenants and agreements may cause the opposed
Party irreparable harm and significant injury, the amount of which will be extremely difficult to estimate and ascertain, thus
potentially making any remedy at law or in damages inadequate. Therefore, each Party agrees that an opposed Party shall be entitled
to seek specific performance, an order restraining any breach or threatened breach of Article VII and all other provisions of this
Agreement, and any other equitable relief (including but not limited to temporary, preliminary and/or permanent injunctive relief).
This right shall be in addition to and not exclusive of any other remedy available to such other Party at law or in equity.

 

    	 

    	 

    

  

11.15         Interpretation.
The language used in this Agreement is the language chosen by the Parties to express their mutual intent, and no provision of this
Agreement shall be interpreted for or against a Party because that Party or its attorney drafted the provision.

 

11.16         Construction.
The words “include,” “includes” and “including” shall be deemed to be followed by the phrase
“without limitation.” All references herein to Articles, Sections and Schedules shall be deemed references to Articles
and Sections of, and Schedules to, this Agreement unless the context shall otherwise require.

 

11.17         Counterparts.
This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed
to be one and the same instrument. A facsimile or a portable document format (.pdf) copy of this Agreement, including the signature
pages, will be deemed an original.

 

[the remainder of this page
has been left blank intentionally]

 

    	 

    	 

    

 

 

 

IN WITNESS WHEREOF,
the Parties have caused this License Agreement to be executed and delivered by their respective duly authorized officers as of
the day and year first above written.

 

LIGAND PHARMACEUTICALS INCORPORATED

 

	By: 	/s/ Matthew W. Foehr	 

 

	Name:	Matthew W. Foehr	 

 

	Title: 	EVP/COO	 

 

	TG THERAPEUTICS, INC.

 

	By: 	/s/ Michael
    S. Weiss	 

 

	Name:	Michael S. Weiss	 

 

	Title: 	Executive
    Chairman, Interim President and Chief Executive Officer	 

 

    	 

    	 

    

  

Schedule 1

 

Compounds*

 

 

* Confidential
material redacted and filed separately with the Commission.

 

    	 

    	 

    

  

Schedule 2

 

Licensor
Know-How*

 

 

* Confidential
material redacted and filed separately with the Commission.

 

    	 

    	 

    

  

Schedule 3

 

Licensor
Patent Rights*

 

 

* Confidential
material redacted and filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]